135 results on '"Nandini Dendukuri"'
Search Results
2. Serodiagnosis of tuberculosis in Asian elephants (Elephas maximus) in Southern India: a latent class analysis.
- Author
-
Shalu Verma-Kumar, David Abraham, Nandini Dendukuri, Jacob Varghese Cheeran, Raman Sukumar, and Kithiganahalli Narayanaswamy Balaji
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Mycobacterium tuberculosis, a causative agent of chronic tuberculosis disease, is widespread among some animal species too. There is paucity of information on the distribution, prevalence and true disease status of tuberculosis in Asian elephants (Elephas maximus). The aim of this study was to estimate the sensitivity and specificity of serological tests to diagnose M. tuberculosis infection in captive elephants in southern India while simultaneously estimating sero-prevalence. METHODOLOGY/PRINCIPAL FINDINGS: Health assessment of 600 elephants was carried out and their sera screened with a commercially available rapid serum test. Trunk wash culture of select rapid serum test positive animals yielded no animal positive for M. tuberculosis isolation. Under Indian field conditions where the true disease status is unknown, we used a latent class model to estimate the diagnostic characteristics of an existing (rapid serum test) and new (four in-house ELISA) tests. One hundred and seventy nine sera were randomly selected for screening in the five tests. Diagnostic sensitivities of the four ELISAs were 91.3-97.6% (95% Credible Interval (CI): 74.8-99.9) and diagnostic specificity were 89.6-98.5% (95% CI: 79.4-99.9) based on the model we assumed. We estimate that 53.6% (95% CI: 44.6-62.8) of the samples tested were free from infection with M. tuberculosis and 15.9% (97.5% CI: 9.8 - to 24.0) tested positive on all five tests. CONCLUSIONS/SIGNIFICANCE: Our results provide evidence for high prevalence of asymptomatic M. tuberculosis infection in Asian elephants in a captive Indian setting. Further validation of these tests would be important in formulating area-specific effective surveillance and control measures.
- Published
- 2012
- Full Text
- View/download PDF
3. Correction: Serodiagnosis of Tuberculosis in Asian Elephants () in Southern India: A Latent Class Analysis.
- Author
-
Shalu Verma-Kumar, David Abraham, Nandini Dendukuri, Jacob Varghese Cheeran, Raman Sukumar, and Kithiganahalli Narayanaswamy Balaji
- Subjects
Medicine ,Science - Published
- 2012
- Full Text
- View/download PDF
4. TB screening in Canadian health care workers using interferon-gamma release assays.
- Author
-
Alice Zwerling, Mihaela Cojocariu, Fiona McIntosh, Filomena Pietrangelo, Marcel A Behr, Kevin Schwartzman, Andrea Benedetti, Nandini Dendukuri, Dick Menzies, and Madhukar Pai
- Subjects
Medicine ,Science - Abstract
While many North American healthcare institutions are switching from Tuberculin Skin Test (TST) to Interferon-gamma release assays (IGRAs), there is relatively limited data on association between occupational tuberculosis (TB) risk factors and test positivity and/or patterns of test discordance.We recruited a cohort of Canadian health care workers (HCWs) in Montreal, and performed both TST and QuantiFERON-TB Gold In Tube (QFT) tests, and assessed risk factors and occupational exposure.In a cross-sectional analysis of baseline results, the prevalence of TST positivity using the 10 mm cut-off was 5.7% (22/388, 95%CI: 3.6-8.5%), while QFT positivity was 6.2% (24/388, 95%CI: 4-9.1%). Overall agreement between the tests was poor (kappa=0.26), and 8.3% of HCWs had discordant test results, most frequently TST-/QFT+ (17/388, 4.4%). TST positivity was associated with total years worked in health care, non-occupational exposure to TB and BCG vaccination received after infancy or on multiple occasions. QFT positivity was associated with having worked as a HCW in a foreign country.Our results suggest that LTBI prevalence as measured by either the TST or the QFT is low in this HCW population. Of concern is the high frequency of unexplainable test discordance, namely: TST-/QFT+ subjects, and the lack of any association between QFT positivity and clear-cut recent TB exposure. If these discordant results are indeed false positives, the use of QFT in lieu of TST in low TB incidence settings could result in overtreatment of uninfected individuals.
- Published
- 2012
- Full Text
- View/download PDF
5. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis.
- Author
-
Karen R Steingart, Laura L Flores, Nandini Dendukuri, Ian Schiller, Suman Laal, Andrew Ramsay, Philip C Hopewell, and Madhukar Pai
- Subjects
Medicine - Abstract
BackgroundSerological (antibody detection) tests for tuberculosis (TB) are widely used in developing countries. As part of a World Health Organization policy process, we performed an updated systematic review to assess the diagnostic accuracy of commercial serological tests for pulmonary and extrapulmonary TB with a focus on the relevance of these tests in low- and middle-income countries.Methods and findingsWe used methods recommended by the Cochrane Collaboration and GRADE approach for rating quality of evidence. In a previous review, we searched multiple databases for papers published from 1 January 1990 to 30 May 2006, and in this update, we add additional papers published from that period until 29 June 2010. We prespecified subgroups to address heterogeneity and summarized test performance using bivariate random effects meta-analysis. For pulmonary TB, we included 67 studies (48% from low- and middle-income countries) with 5,147 participants. For all tests, estimates were variable for sensitivity (0% to 100%) and specificity (31% to 100%). For anda-TB IgG, the only test with enough studies for meta-analysis, pooled sensitivity was 76% (95% CI 63%-87%) in smear-positive (seven studies) and 59% (95% CI 10%-96%) in smear-negative (four studies) patients; pooled specificities were 92% (95% CI 74%-98%) and 91% (95% CI 79%-96%), respectively. Compared with ELISA (pooled sensitivity 60% [95% CI 6%-65%]; pooled specificity 98% [95% CI 96%-99%]), immunochromatographic tests yielded lower pooled sensitivity (53%, 95% CI 42%-64%) and comparable pooled specificity (98%, 95% CI 94%-99%). For extrapulmonary TB, we included 25 studies (40% from low- and middle-income countries) with 1,809 participants. For all tests, estimates were variable for sensitivity (0% to 100%) and specificity (59% to 100%). Overall, quality of evidence was graded very low for studies of pulmonary and extrapulmonary TB.ConclusionsDespite expansion of the literature since 2006, commercial serological tests continue to produce inconsistent and imprecise estimates of sensitivity and specificity. Quality of evidence remains very low. These data informed a recently published World Health Organization policy statement against serological tests. Please see later in the article for the Editors' Summary.
- Published
- 2011
- Full Text
- View/download PDF
6. Tuberculosis infection among young nursing trainees in South India.
- Author
-
Devasahayam J Christopher, Peter Daley, Lois Armstrong, Prince James, Richa Gupta, Beulah Premkumar, Joy Sarojini Michael, Vedha Radha, Alice Zwerling, Ian Schiller, Nandini Dendukuri, and Madhukar Pai
- Subjects
Medicine ,Science - Abstract
Among healthcare workers in developing countries, nurses spend a large amount of time in direct contact with tuberculosis (TB) patients, and are at high risk for acquisition of TB infection and disease. To better understand the epidemiology of nosocomial TB among nurses, we recruited a cohort of young nursing trainees at Christian Medical College, a large, tertiary medical school hospital in Southern India.Among 535 nursing students enrolled in 2007, 468 gave consent to participate, and 436 underwent two-step tuberculin skin testing (TST). A majority (95%) were females, and almost 80% were under 22 years of age. Detailed TB exposure information was obtained using interviews and clinical log books. Prevalence of latent TB infection (LTBI) was estimated using Bayesian latent class analyses (LCA). Logistic regression analyses were done to determine the association between LTBI prevalence and TB exposure and risk factors. 219 of 436 students (50.2%, 95% CI: 45.4-55.0) were TST positive using the 10 mm or greater cut-off. Based on the LCA, the prevalence of LTBI was 47.8% (95% credible interval 17.8% to 65.6%). In the multivariate analysis, TST positivity was strongly associated with time spent in health care, after adjusting for age at entry into healthcare.Our study showed a high prevalence of LTBI even in young nursing trainees. With the recent TB infection control (TBIC) policy guidance from the World Health Organization as the reference, Indian healthcare providers and the Indian Revised National TB Control Programme will need to implement TBIC interventions, and enhance capacity for TBIC at the country level. Young trainees and nurses, in particular, will need to be targeted for TBIC interventions.
- Published
- 2010
- Full Text
- View/download PDF
7. Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards.
- Author
-
Patricia Scolari Fontela, Nitika Pant Pai, Ian Schiller, Nandini Dendukuri, Andrew Ramsay, and Madhukar Pai
- Subjects
Medicine ,Science - Abstract
Poor methodological quality and reporting are known concerns with diagnostic accuracy studies. In 2003, the QUADAS tool and the STARD standards were published for evaluating the quality and improving the reporting of diagnostic studies, respectively. However, it is unclear whether these tools have been applied to diagnostic studies of infectious diseases. We performed a systematic review on the methodological and reporting quality of diagnostic studies in TB, malaria and HIV.We identified diagnostic accuracy studies of commercial tests for TB, malaria and HIV through a systematic search of the literature using PubMed and EMBASE (2004-2006). Original studies that reported sensitivity and specificity data were included. Two reviewers independently extracted data on study characteristics and diagnostic accuracy, and used QUADAS and STARD to evaluate the quality of methods and reporting, respectively.Ninety (38%) of 238 articles met inclusion criteria. All studies had design deficiencies. Study quality indicators that were met in less than 25% of the studies included adequate description of withdrawals (6%) and reference test execution (10%), absence of index test review bias (19%) and reference test review bias (24%), and report of uninterpretable results (22%). In terms of quality of reporting, 9 STARD indicators were reported in less than 25% of the studies: methods for calculation and estimates of reproducibility (0%), adverse effects of the diagnostic tests (1%), estimates of diagnostic accuracy between subgroups (10%), distribution of severity of disease/other diagnoses (11%), number of eligible patients who did not participate in the study (14%), blinding of the test readers (16%), and description of the team executing the test and management of indeterminate/outlier results (both 17%). The use of STARD was not explicitly mentioned in any study. Only 22% of 46 journals that published the studies included in this review required authors to use STARD.Recently published diagnostic accuracy studies on commercial tests for TB, malaria and HIV have moderate to low quality and are poorly reported. The more frequent use of tools such as QUADAS and STARD may be necessary to improve the methodological and reporting quality of future diagnostic accuracy studies in infectious diseases.
- Published
- 2009
- Full Text
- View/download PDF
8. Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors
- Author
-
Noelle Cullinan, Giancarlo Di Giuseppe, Kimberly Caswell, Chantel Cacciotti, Laura Wheaton, David Malkin, Ian Schiller, Paul C. Nathan, Lara Reichman, Catherine Goudie, Jason D. Pole, Mohammed Mamun, Paul Gibson, Bruna Di Monte, William D. Foulkes, Nandini Dendukuri, Donna L. Johnston, and Adam Fleming
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Adolescent ,Childhood cancer ,MEDLINE ,Young Adult ,Cancer Survivors ,Internal medicine ,medicine ,Humans ,Screening tool ,Child ,Early Detection of Cancer ,Retrospective Studies ,business.industry ,Cancer predisposition ,Cancer ,Neoplasms, Second Primary ,medicine.disease ,Logistic Models ,Child, Preschool ,Female ,business - Abstract
PURPOSE Childhood cancer survivors (CCS) are at risk of developing subsequent malignant neoplasms (SMNs) resulting from exposure to prior therapies. CCS with underlying cancer predisposition syndromes are at additional genetic risk of SMN development. The McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool identifies children with cancer at increased likelihood of having a cancer predisposition syndrome, guiding clinicians through a series of Yes or No questions that generate a recommendation for or against genetic evaluation. We evaluated MIPOGG's ability to predict SMN development in CCS. METHODS Using the provincial cancer registry (Ontario, Canada), and adopting a nested case-control approach, we identified CCS diagnosed and/or treated for a primary malignancy before age 18 years (1986-2015). CCS who developed an SMN (cases) were matched, by primary cancer and year of diagnosis, with CCS who did not develop an SMN (controls) over the same period (1:5 ratio). Potential predictors for SMN development (chemotherapy, radiation, and MIPOGG output) were applied retrospectively using clinical data pertaining to the first malignancy. Conditional logistic regression models estimated hazard ratios and 95% CIs associated with each covariate, alone and in combination, for SMN development. RESULTS Of 13,367 children with a primary cancer, 317 (2.4%) developed an SMN and were matched to 1,569 controls. A MIPOGG output recommending evaluation was significantly associated with SMN development (hazard ratio 1.53; 95% CI, 1.06 to 2.19) in a multivariable model that included primary cancer therapy exposures. MIPOGG was predictive of SMN development, showing value in nonhematologic malignancies and in CCS not exposed to radiation. CONCLUSION MIPOGG has additional value for SMN prediction beyond treatment exposures and may be beneficial in decision making for enhanced individualized SMN surveillance strategies for CCS.
- Published
- 2021
9. The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey
- Author
-
Josep Rodés-Cabau, Luiz F. Ybarra, Warren Ball, Neil Brass, Steve Miner, Geoffrey Puley, Alan Barolet, Kunal Minhas, Steven Hodge, Michael J Curtis, Donald A. Palisaitis, James M. Brophy, Shy Amlani, Robert Breton, Marco Spaziano, Jean-Michel Potvin, Hahn Hoe Kim, Alireza Bagherli, Jason Orvold, Sam Radhakrishnan, Paul Malik, Samer Mansour, Aun-Yeong Chong, Israth Jahan, Simon Bérubé, Dominique Joyal, Madhu K. Natarajan, David A. Wood, Jean-François Tanguay, François Gobeil, Kevin R. Bainey, Andrea MacDougall, Neil P Fam, Kevin McKenzie, Sohrab Lutchmedial, Albert W. Chan, Tinouch Haghighat, Hussein K Beydoun, Franco Colizza, Brendan P. Parfrey, Rodney Zimmermann, Stéphane Rinfret, John G. Webb, Nandini Dendukuri, Ram Vijayaraghaban, and Christian Constance
- Subjects
Coronary angiography ,medicine.medical_specialty ,Interventional cardiology ,Coronavirus disease 2019 (COVID-19) ,business.industry ,medicine.medical_treatment ,Rate ratio ,medicine.disease ,St elevation myocardial infarction ,Internal medicine ,RC666-701 ,Pandemic ,medicine ,Cardiology ,Diseases of the circulatory (Cardiovascular) system ,Original Article ,cardiovascular diseases ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Cardiac catheterization - Abstract
Background: As a result of the COVID-19 pandemic first wave, reductions in ST-elevation myocardial infarction (STEMI) invasive care, ranging from 23% to 76%, have been reported from various countries. Whether this change had any impact on coronary angiography (CA) volume or on mechanical support device use for STEMI and post-STEMI mechanical complications in Canada is unknown. Methods: We administered a Canada-wide survey to all cardiac catheterization laboratory directors, seeking the volume of CA use for STEMI performed during the period from March 1 2020 to May 31, 2020 (pandemic period), and during 2 control periods (March 1, 2019 to May 31, 2019 and March 1, 2018 to May 31, 2018). The number of left ventricular support devices used, as well as the number of ventricular septal defects and papillary muscle rupture cases diagnosed, was also recorded. We also assessed whether the number of COVID-19 cases recorded in each province was associated with STEMI-related CA volume. Results: A total of 41 of 42 Canadian catheterization laboratories (98%) provided data. There was a modest but statistically significant 16% reduction (incidence rate ratio [IRR] 0.84; 95% confidence interval 0.80-0.87) in CA for STEMI during the first wave of the pandemic, compared to control periods. IRR was not associated with provincial COVID-19 caseload. We observed a 26% reduction (IRR 0.74; 95% confidence interval 0.61-0.89) in the use of intra-aortic balloon pump use for STEMI. Use of an Impella pump and mechanical complications from STEMI were exceedingly rare. Conclusions: We observed a modest 16% decrease in use of CA for STEMI during the pandemic first wave in Canada, lower than the level reported in other countries. Provincial COVID-19 caseload did not influence this reduction. Résumé: Introduction: Après la première vague de la pandémie de COVID-19, de nombreux pays ont déclaré une réduction de 23 % à 76 % des soins invasifs de l'infarctus du myocarde avec élévation du segment ST (STEMI). On ignore si ce changement a entraîné des répercussions sur le volume d'angiographies coronariennes (AC) ou sur l'utilisation des dispositifs d'assistance mécanique lors de STEMI et des complications mécaniques post-STEMI au Canada. Méthodes: Nous avons réalisé un sondage pancanadien auprès de tous les directeurs de laboratoire de cathétérisme cardiaque pour obtenir le volume d'utilisation des AC lors des STEMI réalisées durant la période du 1er mars 2020 au 31 mai 2020 (période de pandémie) et durant 2 périodes témoins (1er mars 2019 au 31 mai 2019 et 1er mars 2018 au 31 mai 2018). Le nombre de dispositifs d'assistance ventriculaire gauche utilisés et le nombre de cas de communications interventriculaires et de ruptures du muscle papillaire diagnostiqués ont également été enregistrés. Nous avons aussi évalué si le nombre de cas de COVID-19 enregistrés dans chaque province était associé au volume d'AC liées aux STEMI. Résultats: Au total, 41 des 42 laboratoires canadiens de cathétérisme (98 %) ont fourni des données. Lors de la comparaison de la première vague de la pandémie aux périodes témoins, nous avons noté une réduction modeste, mais significative, sur le plan statistique de 16 % (ratio du taux d'incidence [RTI] 0,84; intervalle de confiance à 95 % 0,80-0,87) des AC lors de STEMI. Le RTI n’était pas associé au nombre provincial de cas de COVID-19. Nous avons observé une réduction de 26 % (RTI 0,74; intervalle de confiance à 95 % 0,61-0,89) de l'utilisation de pompes à ballonnet intra-aortique lors de STEMI. L'utilisation d'une pompe Impella et les complications mécaniques après les STEMI étaient extrêmement rares. Conclusions: Nous avons observé une diminution modeste de 16 % de l'utilisation des AC lors de STEMI durant la première vague de la pandémie au Canada, soit une diminution plus faible que ce que les autres pays ont signalé. Le nombre provincial de cas de COVID-19 n'a pas influencé cette réduction.
- Published
- 2021
10. Impact of decreasing cerebrospinal fluid enterovirus PCR turnaround time on costs and management of children with suspected enterovirus meningitis
- Author
-
Cedric P. Yansouni, Marc Beltempo, Mohammad Alghounaim, MinGi Cho, Nandini Dendukuri, Chelsea Caya, and Jesse Papenburg
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Time Factors ,030106 microbiology ,Reference laboratory ,medicine.disease_cause ,Polymerase Chain Reaction ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Medical microbiology ,Internal medicine ,Enterovirus Infections ,medicine ,Humans ,030212 general & internal medicine ,Child ,Pleocytosis ,Enterovirus ,Retrospective Studies ,business.industry ,Enterovirus meningitis ,Disease Management ,Retrospective cohort study ,General Medicine ,Length of Stay ,medicine.disease ,Meningitis, Viral ,Anti-Bacterial Agents ,Infectious Diseases ,Child, Preschool ,Female ,business ,Meningitis - Abstract
To estimate the impact of implementing in-hospital enterovirus (EV) polymerase chain reaction (PCR) testing of cerebrospinal fluid (CSF) with same-day turn-around-time (TAT) on length-of-stay (LOS), antibiotic use and on cost per patient with suspected EV meningitis, compared with testing at an outside reference laboratory. A model-based analysis using a retrospective cohort of all hospitalized children with CSF EV PCR testing done between November 2013 and 2017. The primary outcome measured was the potential date of discharge if the EV PCR result had been available on the same day. Patients with positive EV PCR were considered for potential earlier discharge once clinically stable with no reason for hospitalization other than intravenous antibiotics. Descriptive statistics and cost-sensitivity analyses were performed. CSF EV PCR testing was done on 153 patients, of which 44 (29%) had a positive result. Median test TAT was 5.3 days (IQR 3.9-7.6). Median hospital LOS was 5 days (IQR 3-12). Most (86%) patients received intravenous antibiotics with mean duration of 5.72 ± 6.51 days. No patients with positive EV PCR had a serious bacterial infection. We found that same-day test TAT would reduce LOS and duration of intravenous antibiotics by 0.50 days (95%CI 0.33-0.68) and 0.67 days (95%CI 0.42-0.91), respectively. Same-day test TAT was associated with a cost reduction of 342.83CAD (95%CI 178.14-517.00) per patient with suspected EV meningitis. Compared with sending specimens to a reference laboratory, performing CSF EV PCR in-hospital with same-day TAT was associated with decreased LOS, antibiotic therapy, and cost per patient.
- Published
- 2020
11. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes
- Author
-
Josée Brossard, Kathleen Felton, Jemma Say, Adam Fleming, Valerie Larouche, Ronald Grant, Katherine A Blood, Uri Tabori, Melissa Tachdjian, Chantel Cacciotti, Rawan Hammad, Noelle Cullinan, Catherine Goudie, Vijay Ramaswamy, Lucie Lafay-Cousin, Kalene van Engelen, Kim E. Nichols, Ledia Brunga, Linlea Armstrong, Kimberly Caswell, Stephanie Vairy, Jonathan D. Wasserman, Mary Egan Clark, Conrad V. Fernandez, Katherine M. Tucker, Nandini Dendukuri, James A. Whitlock, Ian Schiller, David Malkin, Gino Somers, Annie-Kim Toupin, Nada Jabado, M. Stephen Meyn, Nicolas Waespe, Sonia Cellot, Daniel Sinnett, Paul Gibson, My Linh Thibodeau, Donna L. Johnston, William D. Foulkes, Rebecca J. Deyell, Angela Punnett, David S. Ziegler, Irene Lara-Corrales, Junne Kamihara, Sarah R. Kane, Meghan Pike, Natalie Mathews, Catherine Clinton, Renee Perrier, Lynn W. Harrison, Meredith S. Irwin, Noemi Fuentes-Bolanos, Orli Michaeli, Meera Warby, Adam Shlien, Leora Witkowski, Anita Villani, Hallie Coltin, Paul C. Nathan, and Lara Reichman
- Subjects
Cancer Research ,medicine.medical_specialty ,Referral ,Genetic counseling ,Internal medicine ,Neoplasms ,Medicine ,Humans ,In patient ,Genetic Predisposition to Disease ,Genetic Testing ,Medical diagnosis ,610 Medicine & health ,Child ,Early Detection of Cancer ,Genetic testing ,Original Investigation ,medicine.diagnostic_test ,business.industry ,Cancer predisposition ,Cancer ,Syndrome ,medicine.disease ,Oncology ,Child, Preschool ,business ,Risk assessment ,360 Social problems & social services - Abstract
Importance Prompt recognition of a child with a cancer predisposition syndrome (CPS) has implications for cancer management, surveillance, genetic counseling, and cascade testing of relatives. Diagnosis of CPS requires practitioner expertise, access to genetic testing, and test result interpretation. This diagnostic process is not accessible in all institutions worldwide, leading to missed CPS diagnoses. Advances in electronic health technology can facilitate CPS risk assessment. Objective To evaluate the diagnostic accuracy of a CPS prediction tool (McGill Interactive Pediatric OncoGenetic Guidelines [MIPOGG]) in identifying children with cancer who have a low or high likelihood of having a CPS. Design, Setting, and Participants In this international, multicenter diagnostic accuracy study, 1071 pediatric (
- Published
- 2021
12. Antimicrobial Stewardship in Bronchiolitis: A Retrospective Cohort Study of Three PICUs in Canada
- Author
-
Kim C. Noël, Patricia S. Fontela, James Dayre McNally, Nisha Thampi, Marie-Astrid Lefebvre, Christina Maratta, Ahmed Almadani, Nandini Dendukuri, Ingrid Tam, Nada A. Aljassim, Caroline Quach, Philippe Jouvet, Jesse Papenburg, Shauna O'Donnell, and Samara R. Zavalkoff
- Subjects
medicine.medical_specialty ,Canada ,Critical Care and Intensive Care Medicine ,Logistic regression ,Intensive Care Units, Pediatric ,Antimicrobial Stewardship ,Anti-Infective Agents ,Interquartile range ,Internal medicine ,medicine ,Antimicrobial stewardship ,Bronchiolitis, Viral ,Humans ,Child ,Retrospective Studies ,business.industry ,Infant ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Antimicrobial ,Discontinuation ,Bronchiolitis ,Pediatrics, Perinatology and Child Health ,business - Abstract
OBJECTIVES To determine the association between the implementation of an antimicrobial stewardship program at a local PICU and to determine the association between the presence of an antimicrobial stewardship programs and antimicrobial use across three Canadian PICUs, among critically ill children with bronchiolitis. DESIGN A multicenter retrospective cohort study. SETTING Three Canadian PICUs over two winter seasons. INTERVENTIONS An antimicrobial stewardship program was implemented at PICU 1 at the end of season 1. PATIENTS Patients less than or equal to 2 years old admitted with bronchiolitis. MEASUREMENTS AND MAIN RESULTS We used regression models with an interaction term between site (PICU 1 and PICU 2) and season (1 and 2) as the primary analysis to determine the association between implementation of an antimicrobial stewardship program at PICU 1 and 1) the proportion of antimicrobials discontinued 72 hours after hospital admission (logistic regression), 2) antimicrobial treatment duration (negative binomial regression), and 3) antimicrobial prescriptions within 48 hours of hospital admission (logistic regression). As a secondary analysis, we determined the association between having an antimicrobial stewardship program present and the aforementioned outcomes across the three PICUs. A total of 372 patients were included. During seasons 1 and 2, median age was 2.2 months (interquartile range, 1.2-6.2 mo) and 2.1 months (interquartile range, 1.3-6.8 mo), respectively. Among patients with viral bronchiolitis, implementation of an antimicrobial stewardship program at PICU 1 was associated with increased odds of discontinuing antimicrobials (odds ratio, 25.63; 95% CI, 2.86-326.29), but not with antimicrobial duration (odds ratio, 0.56; 95% CI, 0.31-1.02) or antimicrobial prescriptions (odds ratio, 0.33; 95% CI, 0.10-1.04). The presence of an antimicrobial stewardship program was similarly associated with antimicrobial discontinuation among patients with viral bronchiolitis (odds ratio, 20.79; 95% CI, 2.46-244.92), but not with antimicrobial duration (odds ratio, 0.57; 95% CI, 0.32-1.03) or antimicrobial prescriptions (odds ratio, 0.37; 95% CI, 0.12-1.11). CONCLUSIONS Antimicrobial stewardship programs were associated with increased likelihood of discontinuing antimicrobial treatments in the PICU patients with viral bronchiolitis. However, larger studies are needed to further determine the role of an antimicrobial stewardship programs in reducing unnecessary antimicrobial use in this patient population.
- Published
- 2021
13. Antiviral Use in Canadian Children Hospitalized for Influenza
- Author
-
Christina Bancej, Kayur Mehta, Taj Jadavji, Manish Sadarangani, Wendy Vaudry, Nandini Dendukuri, Shaun K. Morris, Julie A. Bettinger, Scott A. Halperin, and Jesse Papenburg
- Subjects
Male ,medicine.medical_specialty ,Canada ,Adolescent ,Comorbidity ,Antiviral Agents ,Drug Utilization Review ,Interquartile range ,Internal medicine ,Influenza, Human ,Antimicrobial stewardship ,Medicine ,Humans ,Child ,Influenza treatment ,business.industry ,Age Factors ,Infant ,Odds ratio ,Guideline ,medicine.disease ,Monitoring program ,Confidence interval ,Drug Utilization ,Hospitalization ,Pneumonia ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Multivariate Analysis ,Female ,Guideline Adherence ,business - Abstract
OBJECTIVES Antivirals are recommended for children hospitalized with influenza but are underutilized. We describe antiviral prescribing during influenza admissions in Canadian pediatric centers and identify factors associated with antiviral use. METHODS We performed active surveillance for laboratory-confirmed influenza hospitalizations among children ≤16 years old at the 12 Canadian Immunization Monitoring Program Active hospitals, from 2010–2011 to 2018–2019. Logistic regression analyses were used to identify factors associated with antiviral use. RESULTS Among 7545 patients, 57.4% were male; median age was 3 years (interquartile range: 1.1–6.3). Overall, 41.3% received antiviral agents; 72.8% received antibiotics. Antiviral use varied across sites (range, 10.2% to 81.1%) and influenza season (range, 19.9% to 59.6%) and was more frequent in children with ≥1 chronic health condition (52.7% vs 36.7%; P < .001). On multivariable analysis, factors associated with antiviral use included older age (adjusted odds ratio [aOR] 1.04 [95% confidence interval (CI), 1.02–1.05]), more recent season (highest aOR 9.18 [95% CI, 6.70–12.57] for 2018–2019), admission during peak influenza period (aOR 1.37 [95% CI, 1.19–1.58]), availability of local treatment guideline (aOR 1.54 [95% CI, 1.17–2.02]), timing of laboratory confirmation (highest aOR 2.67 [95% CI, 1.97–3.61] for result available before admission), presence of chronic health conditions (highest aOR 4.81 [95% CI, 3.61–6.40] for cancer), radiographically confirmed pneumonia (aOR 1.39 [95% CI, 1.20–1.60]), antibiotic treatment (aOR 1.51 [95% CI, 1.30–1.76]), respiratory support (1.57 [95% CI, 1.19–2.08]), and ICU admission (aOR 3.62 [95% CI, 2.88–4.56]). CONCLUSIONS Influenza antiviral agents were underused in Canadian pediatric hospitals, including among children with high-risk chronic health conditions. Prescribing varied considerably across sites, increased over time, and was associated with patient and hospital-level characteristics. Multifaceted hospital-based interventions are warranted to strengthen adherence to influenza treatment guidelines and antimicrobial stewardship practices.
- Published
- 2021
14. Recurrent Traumatic Brain Injury Surveillance Using Administrative Health Data: A Bayesian Latent Class Analysis
- Author
-
Oliver Lasry, Nandini Dendukuri, Judith Marcoux, and David L. Buckeridge
- Subjects
medicine.medical_specialty ,recurrence ,recurrent traumatic brain injury ,Traumatic brain injury ,Psychological intervention ,Bayesian analysis ,Context (language use) ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,medicine ,latent class analysis ,030212 general & internal medicine ,RC346-429 ,Original Research ,business.industry ,Incidence (epidemiology) ,traumatic brain injury ,Gold standard ,medicine.disease ,Latent class model ,Neurology ,Radiological weapon ,Emergency medicine ,surveillance ,Neurology (clinical) ,Neurology. Diseases of the nervous system ,business ,030217 neurology & neurosurgery - Abstract
Background: The initial injury burden from incident TBI is significantly amplified by recurrent TBI (rTBI). Unfortunately, research assessing the accuracy to conduct rTBI surveillance is not available. Accurate surveillance information on recurrent injuries is needed to justify the allocation of resources to rTBI prevention and to conduct high quality epidemiological research on interventions that mitigate this injury burden. This study evaluates the accuracy of administrative health data (AHD) surveillance case definitions for rTBI and estimates the 1-year rTBI incidence adjusted for measurement error.Methods: A 25% random sample of AHD for Montreal residents from 2000 to 2014 was used in this study. Four widely used TBI surveillance case definitions, based on the International Classification of Disease and on radiological exams of the head, were applied to ascertain suspected rTBI cases. Bayesian latent class models were used to estimate the accuracy of each case definition and the 1-year rTBI measurement-error-adjusted incidence without relying on a gold standard rTBI definition that does not exist, across children ( =65 years).Results: The adjusted 1-year rTBI incidence was 4.48 (95% CrI 3.42, 6.20) per 100 person-years across all age groups, as opposed to a crude estimate of 8.03 (95% CrI 7.86, 8.21) per 100 person-years. Patients with higher severity index TBI had a significantly higher incidence of rTBI compared to patients with lower severity index TBI. The case definition that identified patients undergoing a radiological examination of the head in the context of any traumatic injury was the most sensitive across children [0.46 (95% CrI 0.33, 0.61)], adults [0.79 (95% CrI 0.64, 0.94)], and elderly [0.87 (95% CrI 0.78, 0.95)]. The most specific case definition was the discharge abstract database in children [0.99 (95% CrI 0.99, 1.00)], and emergency room visits claims in adults/elderly [0.99 (95% CrI 0.99, 0.99)]. Median time to rTBI was the shortest in adults (75 days) and the longest in children (120 days).Conclusion: Conducting accurate surveillance and valid epidemiological research for rTBI using AHD is feasible when measurement error is accounted for.
- Published
- 2021
15. Association between cognitive reserve and cognitive performance in people with HIV: a systematic review and meta-analysis
- Author
-
Navaldeep Kaur, Nandini Dendukuri, Marie-Josée Brouillette, Nancy E. Mayo, and Lesley K. Fellows
- Subjects
Health (social science) ,Social Psychology ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,03 medical and health sciences ,fluids and secretions ,0302 clinical medicine ,Cognitive Reserve ,parasitic diseases ,Humans ,Medicine ,Cognitive Dysfunction ,030212 general & internal medicine ,Effects of sleep deprivation on cognitive performance ,Association (psychology) ,Cognitive reserve ,030505 public health ,business.industry ,Public Health, Environmental and Occupational Health ,Cognition ,Cross-Sectional Studies ,Meta-analysis ,0305 other medical science ,business ,Clinical psychology - Abstract
Cognitive reserve is a potential explanation for the disparity between brain pathology and its clinical manifestations. The main objective of this study was to estimate, based on published studies, the strength of the association between cognitive reserve and cognitive performance in individuals with HIV. A systematic literature search using Ovid MEDLINE, PsychINFO, and EMBASE was performed to identify studies published between 1990 and 2016 that quantified the association between cognitive reserve and cognitive performance in HIV. A random-effects meta-analysis was used to compute a summary estimate (Cohen's
- Published
- 2019
16. Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
- Author
-
Elisa Zaragoza-Macias, Nandini Dendukuri, Ariane Marelli, and Ali N. Zaidi
- Subjects
medicine.medical_specialty ,Ejection fraction ,Heart disease ,medicine.drug_class ,business.industry ,medicine.disease ,dextro-Transposition of the great arteries ,law.invention ,Randomized controlled trial ,law ,Meta-analysis ,Internal medicine ,Heart failure ,ACE inhibitor ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Beta blocker ,medicine.drug - Abstract
Patients with systemic morphological right ventricles (RVs), including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries with a Mustard or Senning atrial baffle repair, have a high likelihood of developing systemic ventricular dysfunction. Unfortunately, there are a limited number of clinical studies on the efficacy of medical therapy for systemic RV dysfunction. We performed a systematic review and meta-analysis to assess the effect of angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta blockers, and aldosterone antagonists in adults with systemic RVs. The inclusion criteria included age ≥18 years, systemic RVs, and at least 3 months of treatment with ACE inhibitor, ARB, beta blocker, or aldosterone antagonist. The outcomes included RV end-diastolic and end-systolic dimensions, RV ejection fraction, functional class, and exercise capacity. EMBASE, PubMed, and Cochrane databases were searched. The selected data were pooled and analyzed with the DerSimonian-Laird random-effects meta-analysis model. Between-study heterogeneity was assessed with Cochran's Q test. A Bayesian meta-analysis model was also used in the event that heterogeneity was low. Bias assessment was performed with the Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool, and statistical risk of bias was assessed with Begg and Mazumdar's test and Egger's test. Six studies met the inclusion criteria, contributing a total of 187 patients; treatment with beta blocker was the intervention that could not be analyzed because of the small number of patients and diversity of outcomes reported. After at least 3 months of treatment with ACE inhibitors, ARBs, or aldosterone antagonists, there was no statistically significant change in mean ejection fraction, ventricular dimensions, or peak ventilatory equivalent of oxygen. The methodological quality of the majority of included studies was low, mainly because of a lack of a randomized and controlled design, small sample size, and incomplete follow-up. In conclusion, pooled results across the limited available studies did not provide conclusive evidence with regard to a beneficial effect of medical therapy in adults with systemic RV dysfunction. Randomized controlled trials or comparative-effectiveness studies that are sufficiently powered to demonstrate effect are needed to elucidate the efficacy of ACE inhibitors, ARBs, beta blockers, and aldosterone antagonists in patients with systemic RVs.
- Published
- 2019
17. Interventional Therapy Versus Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
- Author
-
Nandini Dendukuri, Ariane Marelli, Ami B. Bhatt, Elisa Zaragoza-Macias, and Matthew E. Oster
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,Heart disease ,business.industry ,Population ,Septum secundum ,030204 cardiovascular system & hematology ,Cochrane Library ,medicine.disease ,Atrial septal defects ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,medicine ,Observational study ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,education ,business ,Cohort study - Abstract
Secundum atrial septal defect (ASD) is the most common adult congenital heart defect and can present with wide variation in clinical findings. With the intention of preventing morbidity and mortality associated with late presentation of ASD, consensus guidelines have recommended surgical or percutaneous ASD closure in adults with right heart enlargement, with or without symptoms. The aim of the present analysis was to determine if the protective effect of secundum ASD closure in adults could be qualified by pooling data from published studies. A systematic review and meta-analysis were performed by using EMBASE, MEDLINE (through PubMed), and the Cochrane Library databases to assess the effect of secundum ASD percutaneous or surgical closure in unoperated adults ≥18 years of age. Data were pooled across studies with the DerSimonian-Laird random-effects model or a Bayesian meta-analysis model. Between-study heterogeneity was assessed with Cochran's Q test. Bias assessment was performed with the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool, and statistical risk of bias was assessed with Begg and Mazumdar's test and Egger's test. A total of 11 nonrandomized studies met the inclusion criteria, contributing 603 patients. Pooled analysis showed a protective effect of ASD closure on New York Heart Association functional class and on right ventricular systolic pressure, volumes, and dimensions. Two additional studies comprising 652 patients were reviewed separately for mortality outcome and primary outcome of interest because they did not meet the inclusion criteria. Those studies showed that ASD closure was associated with a weak protective effect on adjusted mortality rate but no significant impact on atrial arrhythmias in patients >50 years of age. Across all studies, there was significant heterogeneity between studies for nearly all clinical outcomes. The overall body of evidence was limited to observational cohort studies, the limitations of which make for low-strength evidence. Even within the parameters of the included studies, quality of evidence was further diminished by the lack of well-defined clinical outcomes. In conclusion, pooled data analysis on the impact of secundum ASD closure in adults was notably limited because of the lack of randomized controlled trials in patients with only secundum ASD. The few cohort studies in this population demonstrated improvement in functional status and right ventricular size and function as shown by echocardiogram. However, our findings suggest that at the time of this publication, insufficient data are available to determine the impact of ASD repair on mortality rate in adults.
- Published
- 2019
18. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms
- Author
-
Mandy Yao, Nandini Dendukuri, Adrienne E Shapiro, Mikashmi Kohli, Karen R Steingart, Ian Schiller, David J. Horne, and Jennifer M. Ross
- Subjects
Adult ,medicine.medical_specialty ,Tuberculosis ,medicine.drug_class ,Cross-sectional study ,Antibiotics ,Population ,HIV Infections ,Drug resistance ,Polymerase Chain Reaction ,Sensitivity and Specificity ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Bias ,qv_771 ,Internal medicine ,Drug Resistance, Bacterial ,Diagnosis ,medicine ,Humans ,Pharmacology (medical) ,False Positive Reactions ,030212 general & internal medicine ,education ,Antibiotics, Antitubercular ,False Negative Reactions ,Tuberculosis, Pulmonary ,education.field_of_study ,Bacteriological Techniques ,Infectious disease ,business.industry ,Sputum ,Bayes Theorem ,Mycobacterium tuberculosis ,medicine.disease ,bacterial infections and mycoses ,Cross-Sectional Studies ,Meta-analysis ,qv_268 ,wf_220 ,wf_200 ,Rifampin ,business ,030217 neurology & neurosurgery ,Cohort study - Abstract
Background Tuberculosis is a leading cause of infectious disease‐related death and is one of the top 10 causes of death worldwide. The World Health Organization (WHO) recommends the use of specific rapid molecular tests, including Xpert MTB/RIF or Xpert Ultra, as initial diagnostic tests for the detection of tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis. However, the WHO estimates that nearly one‐third of all active tuberculosis cases go undiagnosed and unreported. We were interested in whether a single test, Xpert MTB/RIF or Xpert Ultra, could be useful as a screening test to close this diagnostic gap and improve tuberculosis case detection. Objectives To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for pulmonary tuberculosis in adults, irrespective of signs or symptoms of pulmonary tuberculosis in high‐risk groups and in the general population. Screening "irrespective of signs or symptoms" refers to screening of people who have not been assessed for the presence of tuberculosis symptoms (e.g. cough). To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra for detecting rifampicin resistance in adults screened for tuberculosis, irrespective of signs and symptoms of pulmonary tuberculosis in high‐risk groups and in the general population. Search methods We searched 12 databases including the Cochrane Infectious Diseases Group Specialized Register, MEDLINE and Embase, on 19 March 2020 without language restrictions. We also reviewed reference lists of included articles and related Cochrane Reviews, and contacted researchers in the field to identify additional studies. Selection criteria Cross‐sectional and cohort studies in which adults (15 years and older) in high‐risk groups (e.g. people living with HIV, household contacts of people with tuberculosis) or in the general population were screened for pulmonary tuberculosis using Xpert MTB/RIF or Xpert Ultra. For tuberculosis detection, the reference standard was culture. For rifampicin resistance detection, the reference standards were culture‐based drug susceptibility testing and line probe assays. Data collection and analysis Two review authors independently extracted data using a standardized form and assessed risk of bias and applicability using QUADAS‐2. We used a bivariate random‐effects model to estimate pooled sensitivity and specificity with 95% credible intervals (CrIs) separately for tuberculosis detection and rifampicin resistance detection. We estimated all models using a Bayesian approach. For tuberculosis detection, we first estimated screening accuracy in distinct high‐risk groups, including people living with HIV, household contacts, people residing in prisons, and miners, and then in several high‐risk groups combined. Main results We included a total of 21 studies: 18 studies (13,114 participants) evaluated Xpert MTB/RIF as a screening test for pulmonary tuberculosis and one study (571 participants) evaluated both Xpert MTB/RIF and Xpert Ultra. Three studies (159 participants) evaluated Xpert MTB/RIF for rifampicin resistance. Fifteen studies (75%) were conducted in high tuberculosis burden and 16 (80%) in high TB/HIV‐burden countries. We judged most studies to have low risk of bias in all four QUADAS‐2 domains and low concern for applicability. Xpert MTB/RIF and Xpert Ultra as screening tests for pulmonary tuberculosis In people living with HIV (12 studies), Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 61.8% (53.6 to 69.9) (602 participants; moderate‐certainty evidence) and 98.8% (98.0 to 99.4) (4173 participants; high‐certainty evidence). Of 1000 people where 50 have tuberculosis on culture, 40 would be Xpert MTB/RIF‐positive; of these, 9 (22%) would not have tuberculosis (false‐positives); and 960 would be Xpert MTB/RIF‐negative; of these, 19 (2%) would have tuberculosis (false‐negatives). In people living with HIV (1 study), Xpert Ultra sensitivity and specificity (95% CI) were 69% (57 to 80) (68 participants; very low‐certainty evidence) and 98% (97 to 99) (503 participants; moderate‐certainty evidence). Of 1000 people where 50 have tuberculosis on culture, 53 would be Xpert Ultra‐positive; of these, 19 (36%) would not have tuberculosis (false‐positives); and 947 would be Xpert Ultra‐negative; of these, 16 (2%) would have tuberculosis (false‐negatives). In non‐hospitalized people in high‐risk groups (5 studies), Xpert MTB/RIF pooled sensitivity and specificity were 69.4% (47.7 to 86.2) (337 participants, low‐certainty evidence) and 98.8% (97.2 to 99.5) (8619 participants, moderate‐certainty evidence). Of 1000 people where 10 have tuberculosis on culture, 19 would be Xpert MTB/RIF‐positive; of these, 12 (63%) would not have tuberculosis (false‐positives); and 981 would be Xpert MTB/RIF‐negative; of these, 3 (0%) would have tuberculosis (false‐negatives). We did not identify any studies using Xpert MTB/RIF or Xpert Ultra for screening in the general population. Xpert MTB/RIF as a screening test for rifampicin resistance Xpert MTB/RIF sensitivity was 81% and 100% (2 studies, 20 participants; very low‐certainty evidence), and specificity was 94% to 100%, (3 studies, 139 participants; moderate‐certainty evidence). Authors' conclusions Of the high‐risks groups evaluated, Xpert MTB/RIF applied as a screening test was accurate for tuberculosis in high tuberculosis burden settings. Sensitivity and specificity were similar in people living with HIV and non‐hospitalized people in high‐risk groups. In people living with HIV, Xpert Ultra sensitivity was slightly higher than that of Xpert MTB/RIF and specificity similar. As there was only one study of Xpert Ultra in this analysis, results should be interpreted with caution. There were no studies that evaluated the tests in people with diabetes mellitus and other groups considered at high‐risk for tuberculosis, or in the general population., Plain language summary How accurate are sputum Xpert tests for screening for active pulmonary tuberculosis and rifampicin resistance in adults whether or not they have tuberculosis symptoms? Why is using Xpert tests to screen for pulmonary tuberculosis important? Tuberculosis is the leading cause of infectious disease‐related death and one of the top 10 causes of death worldwide. The World Health Organization (WHO) recommends using specific rapid tests as initial tests for diagnosing tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis. However, the WHO estimates that nearly one‐third of all active tuberculosis cases go undiagnosed and unreported. Not recognizing tuberculosis when it is present (a false negative test result) may result in illness and death and an increased risk of infecting others. An incorrect diagnosis of tuberculosis (false‐positive result) may mean that people are given antibiotics when there is no benefit to be gained. What is the aim of this review? To estimate the accuracy of Xpert MTB/RIF and Xpert Ultra as screening tests for pulmonary tuberculosis and rifampicin resistance in adults whether or not they have tuberculosis symptoms (such as cough, fever, weight loss, and night sweats). We were interested in how the tests worked in groups at high risk for tuberculosis, including people living with HIV (PLHIV), household contacts of people with tuberculosis, miners, people residing in prisons, people with diabetes, and in the general public. What was studied in this review? Xpert MTB/RIF and Xpert Ultra are rapid tests for simultaneously diagnosing tuberculosis and rifampicin resistance. We combined study results to determine: ‐ sensitivity: people with tuberculosis (rifampicin resistance) correctly diagnosed as having the condition. ‐ specificity: people without tuberculosis (rifampicin resistance) correctly identified as not having the condition. The closer sensitivity and specificity are to 100%, the better the test. What are the main results in this review? Twenty‐one studies: 18 studies (13,114 participants) evaluated Xpert MTB/RIF as a screening test for pulmonary tuberculosis and one study (571 participants) evaluated both Xpert MTB/RIF and Xpert Ultra. Three studies (159 participants) evaluated Xpert MTB/RIF for rifampicin resistance. For every 1000 people tested, if 50 had tuberculosis according to the reference standard: PLHIV ‐ Xpert MTB/RIF (12 studies): · 40 people would test positive, including 9 without tuberculosis (62% sensitivity) · 960 people would test negative, including 19 with tuberculosis (99% specificity) ‐ Xpert Ultra (1 study): · 53 people would test positive, including 19 without tuberculosis (69% sensitivity) · 947 people would test negative, including 16 with tuberculosis (98% specificity) For every 1000 people tested, if 10 had tuberculosis according to the reference standard: Other high‐risk groups combined ‐ Xpert MTB/RIF (5 studies): · 19 people would test positive, including 12 without tuberculosis (69% sensitivity) · 981 people would test negative, including 3 with tuberculosis (99% specificity) For detection of rifampicin resistance, Xpert MTB/RIF sensitivity was 81% and 100% (2 studies) and specificity was 94% to 100% (3 studies). How reliable are the results of the studies in this review? In the included studies, the reference standards for diagnosing pulmonary tuberculosis (culture) and rifampicin resistance (drug susceptibility testing) are likely to have been reliable methods for deciding whether patients really had the conditions. We were fairly confident in the results for Xpert MTB/RIF in PLHIV, and less so for other high‐risk groups. Not enough people have been studied to be confident about the results for Xpert Ultra or for detection of rifampicin resistance. Who do the results of this review apply to? Studies were mainly performed in high tuberculosis and high HIV burden settings. No studies evaluated the tests in people with diabetes mellitus or the general population. What are the implications of this review? In PLHIV, Xpert MTB/RIF as a screening test was accurate for tuberculosis in high tuberculosis burden settings. In high‐risk groups, Xpert MTB/RIF may assist in identifying tuberculosis, but the certainty of evidence is low. In PLHIV, Xpert Ultra sensitivity was slightly higher than that of Xpert MTB/RIF and specificity similar based on one study. There were few studies and few people tested for rifampicin resistance and no studies that evaluated the tests in people with diabetes or in the general population. How up‐to‐date is this review? 19 March 2020.
- Published
- 2021
19. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis
- Author
-
Mikashmi Kohli, Jerry S Zifodya, Frederick Haraka, Jonah S Kreniske, Eleanor A Ochodo, Samuel G Schumacher, Ian Schiller, Nandini Dendukuri, Karen R Steingart, Madhukar Pai, Alice Zwerling, and David J. Horne
- Subjects
History of tuberculosis ,medicine.medical_specialty ,Tuberculosis ,business.industry ,Signs and symptoms ,Rifampicin resistance ,Drug susceptibility ,Drug resistance ,bacterial infections and mycoses ,medicine.disease ,World health ,03 medical and health sciences ,0302 clinical medicine ,Pulmonary tuberculosis ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,business ,030217 neurology & neurosurgery - Abstract
Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health Organization (WHO)-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis. This review builds on our recent extensive Cochrane Review of Xpert MTB/RIF accuracy. Objectives To compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for the detection of pulmonary tuberculosis and detection of rifampicin resistance in adults with presumptive pulmonary tuberculosis. For pulmonary tuberculosis and rifampicin resistance, we also investigated potential sources of heterogeneity. We also summarized the frequency of Xpert Ultra trace-positive results, and estimated the accuracy of Xpert Ultra after repeat testing in those with trace-positive results. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, LILACS, Scopus, the WHO ICTRP, the ISRCTN registry, and ProQuest to 28 January 2020 with no language restriction. Selection criteria We included diagnostic accuracy studies using respiratory specimens in adults with presumptive pulmonary tuberculosis that directly compared the index tests. For pulmonary tuberculosis detection, the reference standards were culture and a composite reference standard. For rifampicin resistance, the reference standards were culture-based drug susceptibility testing and line probe assays. Data collection and analysis Two review authors independently extracted data using a standardized form, including data by smear and HIV status. We assessed risk of bias using QUADAS-2 and QUADAS-C. We performed meta-analyses comparing pooled sensitivities and specificities, separately for pulmonary tuberculosis detection and rifampicin resistance detection, and separately by reference standard. Most analyses used a bivariate random-effects model. For tuberculosis detection, we estimated accuracy in studies in participants who were not selected based on prior microscopy testing or history of tuberculosis. We performed subgroup analyses by smear status, HIV status, and history of tuberculosis. We summarized Xpert Ultra trace results. Main results We identified nine studies (3500 participants): seven had unselected participants (2834 participants). All compared Xpert Ultra and Xpert MTB/RIF for pulmonary tuberculosis detection; seven studies used a paired comparative accuracy design, and two studies used a randomized design. Five studies compared Xpert Ultra and Xpert MTB/RIF for rifampicin resistance detection; four studies used a paired design, and one study used a randomized design. Of the nine included studies, seven (78%) were mainly or exclusively in high tuberculosis burden countries. For pulmonary tuberculosis detection, most studies had low risk of bias in all domains. Pulmonary tuberculosis detection Xpert Ultra pooled sensitivity and specificity (95% credible interval) against culture were 90.9% (86.2 to 94.7) and 95.6% (93.0 to 97.4) (7 studies, 2834 participants; high-certainty evidence) versus Xpert MTB/RIF pooled sensitivity and specificity of 84.7% (78.6 to 89.9) and 98.4% (97.0 to 99.3) (7 studies, 2835 participants; high-certainty evidence). The difference in the accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated at 6.3% (0.1 to 12.8) for sensitivity and -2.7% (-5.7 to -0.5) for specificity. If the point estimates for Xpert Ultra and Xpert MTB/RIF are applied to a hypothetical cohort of 1000 patients, where 10% of those presenting with symptoms have pulmonary tuberculosis, Xpert Ultra will miss 9 cases, and Xpert MTB/RIF will miss 15 cases. The number of people wrongly diagnosed with pulmonary tuberculosis would be 40 with Xpert Ultra and 14 with Xpert MTB/RIF. In smear-negative, culture-positive participants, pooled sensitivity was 77.5% (67.6 to 85.6) for Xpert Ultra versus 60.6% (48.4 to 71.7) for Xpert MTB/RIF; pooled specificity was 95.8% (92.9 to 97.7) for Xpert Ultra versus 98.8% (97.7 to 99.5) for Xpert MTB/RIF (6 studies). In people living with HIV, pooled sensitivity was 87.6% (75.4 to 94.1) for Xpert Ultra versus 74.9% (58.7 to 86.2) for Xpert MTB/RIF; pooled specificity was 92.8% (82.3 to 97.0) for Xpert Ultra versus 99.7% (98.6 to 100.0) for Xpert MTB/RIF (3 studies). In participants with a history of tuberculosis, pooled sensitivity was 84.2% (72.5 to 91.7) for Xpert Ultra versus 81.8% (68.7 to 90.0) for Xpert MTB/RIF; pooled specificity was 88.2% (70.5 to 96.6) for Xpert Ultra versus 97.4% (91.7 to 99.5) for Xpert MTB/RIF (4 studies). The proportion of Ultra trace-positive results ranged from 3.0% to 30.4%. Data were insufficient to estimate the accuracy of Xpert Ultra repeat testing in individuals with initial trace-positive results. Rifampicin resistance detection Pooled sensitivity and specificity were 94.9% (88.9 to 97.9) and 99.1% (97.7 to 99.8) (5 studies, 921 participants; high-certainty evidence) for Xpert Ultra versus 95.3% (90.0 to 98.1) and 98.8% (97.2 to 99.6) (5 studies, 930 participants; high-certainty evidence) for Xpert MTB/RIF. The difference in the accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated at -0.3% (-6.9 to 5.7) for sensitivity and 0.3% (-1.2 to 2.0) for specificity. If the point estimates for Xpert Ultra and Xpert MTB/RIF are applied to a hypothetical cohort of 1000 patients, where 10% of those presenting with symptoms have rifampicin resistance, Xpert Ultra will miss 5 cases, and Xpert MTB/RIF will miss 5 cases. The number of people wrongly diagnosed with rifampicin resistance would be 8 with Xpert Ultra and 11 with Xpert MTB/RIF. We identified a higher number of rifampicin resistance indeterminate results with Xpert Ultra, pooled proportion 7.6% (2.4 to 21.0) compared to Xpert MTB/RIF pooled proportion 0.8% (0.2 to 2.4). The estimated difference in the pooled proportion of indeterminate rifampicin resistance results for Xpert Ultra versus Xpert MTB/RIF was 6.7% (1.4 to 20.1). Authors' conclusions Xpert Ultra has higher sensitivity and lower specificity than Xpert MTB/RIF for pulmonary tuberculosis, especially in smear-negative participants and people living with HIV. Xpert Ultra specificity was lower than that of Xpert MTB/RIF in participants with a history of tuberculosis. The sensitivity and specificity trade-off would be expected to vary by setting. For detection of rifampicin resistance, Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity. Ultra trace-positive results were common. Xpert Ultra and Xpert MTB/RIF provide accurate results and can allow rapid initiation of treatment for rifampicin-resistant and multidrug-resistant tuberculosis.
- Published
- 2021
20. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis
- Author
-
Ian Schiller, Mandy Yao, Todd C. Lee, Alexander Lawandi, Guillaume Butler-Laporte, Nandini Dendukuri, and Emily G. McDonald
- Subjects
medicine.medical_specialty ,Saliva ,Population ,01 natural sciences ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,COVID-19 Testing ,Internal medicine ,Post-hoc analysis ,Internal Medicine ,Credible interval ,Medicine ,Nucleic Acid Amplification Tests ,Humans ,030212 general & internal medicine ,0101 mathematics ,education ,education.field_of_study ,business.industry ,SARS-CoV-2 ,010102 general mathematics ,COVID-19 ,Correction ,Systematic review ,Meta-analysis ,Ambulatory ,business - Abstract
Importance Nasopharyngeal swab nucleic acid amplification testing (NAAT) is the noninvasive criterion standard for diagnosis of coronavirus disease 2019 (COVID-19). However, it requires trained personnel, limiting its availability. Saliva NAAT represents an attractive alternative, but its diagnostic performance is unclear. Objective To assess the diagnostic accuracy of saliva NAAT for COVID-19. Data Sources In this systematic review, a search of the MEDLINE and medRxiv databases was conducted on August 29, 2020, to find studies of diagnostic test accuracy. The final meta-analysis was performed on November 17, 2020. Study Selection Studies needed to provide enough data to measure salivary NAAT sensitivity and specificity compared with imperfect nasopharyngeal swab NAAT as a reference test. An imperfect reference test does not perfectly reflect the truth (ie, it can give false results). Studies were excluded if the sample contained fewer than 20 participants or was neither random nor consecutive. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used to assess the risk of bias. Data Extraction and Synthesis Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed for the systematic review, with multiple authors involved at each stage of the review. To account for the imperfect reference test sensitivity, we used a bayesian latent class bivariate model for the meta-analysis. Main Outcomes and Measures The primary outcome was pooled sensitivity and specificity. Two secondary analyses were performed: one restricted to peer-reviewed studies, and a post hoc analysis limited to ambulatory settings. Results The search strategy yielded 385 references, and 16 unique studies were identified for quantitative synthesis. Eight peer-reviewed studies and 8 preprints were included in the meta-analyses (5922 unique patients). There was significant variability in patient selection, study design, and stage of illness at which patients were enrolled. Fifteen studies included ambulatory patients, and 9 exclusively enrolled from an outpatient population with mild or no symptoms. In the primary analysis, the saliva NAAT pooled sensitivity was 83.2% (95% credible interval [CrI], 74.7%-91.4%) and the pooled specificity was 99.2% (95% CrI, 98.2%-99.8%). The nasopharyngeal swab NAAT had a sensitivity of 84.8% (95% CrI, 76.8%-92.4%) and a specificity of 98.9% (95% CrI, 97.4%-99.8%). Results were similar in secondary analyses. Conclusions and Relevance These results suggest that saliva NAAT diagnostic accuracy is similar to that of nasopharyngeal swab NAAT, especially in the ambulatory setting. These findings support larger-scale research on the use of saliva NAAT as an alternative to nasopharyngeal swabs.
- Published
- 2021
21. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
- Author
-
Nandini Dendukuri, Mandy Yao, Claudia M. Denkinger, Mikashmi Kohli, Keertan Dheda, Ian Schiller, Karen R Steingart, and Samuel G Schumacher
- Subjects
medicine.medical_specialty ,Tuberculosis ,biology ,business.industry ,Rifampicin resistance ,Drug resistance ,bacterial infections and mycoses ,biology.organism_classification ,medicine.disease ,Tuberculous meningitis ,03 medical and health sciences ,0302 clinical medicine ,Mycobacterium tuberculosis complex ,Tuberculosis diagnosis ,Internal medicine ,medicine ,Sputum ,Pharmacology (medical) ,030212 general & internal medicine ,medicine.symptom ,Lymph Node Tuberculosis ,business ,030217 neurology & neurosurgery - Abstract
Background Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely used for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum. To extend our previous review on extrapulmonary tuberculosis (Kohli 2018), we performed this update to inform updated WHO policy (WHO Consolidated Guidelines (Module 3) 2020). Objectives To estimate diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin resistance in adults with presumptive extrapulmonary tuberculosis. Search methods Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, 2 August 2019 and 28 January 2020 (Xpert Ultra studies), without language restriction. Selection criteria Cross‐sectional and cohort studies using non‐respiratory specimens. Forms of extrapulmonary tuberculosis: tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, disseminated tuberculosis. Reference standards were culture and a study‐defined composite reference standard (tuberculosis detection); phenotypic drug susceptibility testing and line probe assays (rifampicin resistance detection). Data collection and analysis Two review authors independently extracted data and assessed risk of bias and applicability using QUADAS‐2. For tuberculosis detection, we performed separate analyses by specimen type and reference standard using the bivariate model to estimate pooled sensitivity and specificity with 95% credible intervals (CrIs). We applied a latent class meta‐analysis model to three forms of extrapulmonary tuberculosis. We assessed certainty of evidence using GRADE. Main results 69 studies: 67 evaluated Xpert MTB/RIF and 11 evaluated Xpert Ultra, of which nine evaluated both tests. Most studies were conducted in China, India, South Africa, and Uganda. Overall, risk of bias was low for patient selection, index test, and flow and timing domains, and low (49%) or unclear (43%) for the reference standard domain. Applicability for the patient selection domain was unclear for most studies because we were unsure of the clinical settings. Cerebrospinal fluid Xpert Ultra (6 studies) Xpert Ultra pooled sensitivity and specificity (95% CrI) against culture were 89.4% (79.1 to 95.6) (89 participants; low‐certainty evidence) and 91.2% (83.2 to 95.7) (386 participants; moderate‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 168 would be Xpert Ultra‐positive: of these, 79 (47%) would not have tuberculosis (false‐positives) and 832 would be Xpert Ultra‐negative: of these, 11 (1%) would have tuberculosis (false‐negatives). Xpert MTB/RIF (30 studies) Xpert MTB/RIF pooled sensitivity and specificity against culture were 71.1% (62.8 to 79.1) (571 participants; moderate‐certainty evidence) and 96.9% (95.4 to 98.0) (2824 participants; high‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 99 would be Xpert MTB/RIF‐positive: of these, 28 (28%) would not have tuberculosis; and 901 would be Xpert MTB/RIF‐negative: of these, 29 (3%) would have tuberculosis. Pleural fluid Xpert Ultra (4 studies) Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) (158 participants; very low‐certainty evidence) and 87.0% (63.1 to 97.9) (240 participants; very low‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 192 would be Xpert Ultra‐positive: of these, 117 (61%) would not have tuberculosis; and 808 would be Xpert Ultra‐negative: of these, 25 (3%) would have tuberculosis. Xpert MTB/RIF (25 studies) Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) (644 participants; low‐certainty evidence) and 98.9% (97.6 to 99.7) (2421 participants; high‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 60 would be Xpert MTB/RIF‐positive: of these, 10 (17%) would not have tuberculosis; and 940 would be Xpert MTB/RIF‐negative: of these, 50 (5%) would have tuberculosis. Lymph node aspirate Xpert Ultra (1 study) Xpert Ultra sensitivity and specificity (95% confidence interval) against composite reference standard were 70% (51 to 85) (30 participants; very low‐certainty evidence) and 100% (92 to 100) (43 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 70 would be Xpert Ultra‐positive and 0 (0%) would not have tuberculosis; 930 would be Xpert Ultra‐negative and 30 (3%) would have tuberculosis. Xpert MTB/RIF (4 studies) Xpert MTB/RIF pooled sensitivity and specificity against composite reference standard were 81.6% (61.9 to 93.3) (377 participants; low‐certainty evidence) and 96.4% (91.3 to 98.6) (302 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 118 would be Xpert MTB/RIF‐positive and 37 (31%) would not have tuberculosis; 882 would be Xpert MTB/RIF‐negative and 19 (2%) would have tuberculosis. In lymph node aspirate, Xpert MTB/RIF pooled specificity against culture was 86.2% (78.0 to 92.3), lower than that against a composite reference standard. Using the latent class model, Xpert MTB/RIF pooled specificity was 99.5% (99.1 to 99.7), similar to that observed with a composite reference standard. Rifampicin resistance Xpert Ultra (4 studies) Xpert Ultra pooled sensitivity and specificity were 100.0% (95.1 to 100.0), (24 participants; low‐certainty evidence) and 100.0% (99.0 to 100.0) (105 participants; moderate‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 100 would be Xpert Ultra‐positive (resistant): of these, zero (0%) would not have rifampicin resistance; and 900 would be Xpert Ultra‐negative (susceptible): of these, zero (0%) would have rifampicin resistance. Xpert MTB/RIF (19 studies) Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9 to 98.8) (148 participants; high‐certainty evidence) and 99.1% (98.0 to 99.7) (822 participants; high‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 105 would be Xpert MTB/RIF‐positive (resistant): of these, 8 (8%) would not have rifampicin resistance; and 895 would be Xpert MTB/RIF‐negative (susceptible): of these, 3 (0.3%) would have rifampicin resistance. Authors' conclusions Xpert Ultra and Xpert MTB/RIF may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across different extrapulmonary specimens: while for most specimens specificity is high, the tests rarely yield a positive result for people without tuberculosis. For tuberculous meningitis, Xpert Ultra had higher sensitivity and lower specificity than Xpert MTB/RIF against culture. Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance. Future research should acknowledge the concern associated with culture as a reference standard in paucibacillary specimens and consider ways to address this limitation.
- Published
- 2021
22. A Longitudinal View of Successful Aging With HIV: Role of Resilience and Environmental Factors
- Author
-
Fiona Smaill, Nancy E. Mayo, Lyne Nadeau, Lesley K. Fellows, Marie-Josée Brouillette, Graham Smith, Nandini Dendukuri, Marianne Harris, and Réjean Thomas
- Subjects
Male ,Gerontology ,Aging ,media_common.quotation_subject ,Social Stigma ,HIV Infections ,030204 cardiovascular system & hematology ,Logistic regression ,Helsinki declaration ,03 medical and health sciences ,Cognition ,0302 clinical medicine ,Quality of life (healthcare) ,030502 gerontology ,Informed consent ,medicine ,Humans ,030212 general & internal medicine ,Social determinants of health ,10. No inequality ,Socioeconomic status ,media_common ,Motivation ,Research ethics ,Successful aging ,Loneliness ,Public Health, Environmental and Occupational Health ,Social Support ,Middle Aged ,Cognitive test ,3. Good health ,Socioeconomic Factors ,Quality of Life ,Female ,Psychological resilience ,medicine.symptom ,0305 other medical science ,Psychology - Abstract
Background: Much attention is paid to the negative aspects of aging with HIV. Less is known about those doing well, yet much could be learned from those aging successfully. Objective: The purpose of this study is to estimate the extent to which people aging with HIV met criteria for successful aging and maintained this status over time. A second objective was to identify factors that placed people at promise for successful aging. Methods: Participants were members of the Positive Brain Health Now (BHN) cohort which recruited from five Canadian sites (2014-2016) with prospective follow-up over 27 months. People ≥50 were classified as aging successfully if they were at or above norms on 7 or 8 of 8 health-related quality of life domains from the RAND-36. Promise factors covered socio-demographic, HIV, co-morbidity, lifestyle, resilience, and environmental domains. Group-based Trajectory Analysis, logistic regression and regression tree analysis, a form of machine learning, were applied. Results: Of the 513 people age ≥50 at study entry, 73 (14·2%) met criteria for successful aging at entry and over time. The most influential factor was loneliness: splitting the sample into two groups with the prevalence of successful aging 28·4% in the not-lonely compared to 4·6% in the lonely. Other influential factors were feeling safe, social network, motivation, stigma, and socioeconomic status. These factors identified 17 sub-groups with at least 30 members with the proportions classified as aging successfully ranging from 0% to 79·4%. Conclusion: The results indicate the important role of social determinants of health in successful aging in people with HIV. Funding Statement: This project was supported by grants from the Canadian Institutes of Health Research (LKF,MJB, NM, TCO-125272), the CIHR Canadian HIV Trials Network (CTN 273), and salary support from the Fonds de Recherche Sante du Quebec (LKF) and the Research Institute of the McGill University Health Centre (MJB). Declaration of Interests: Authors declare that they have no conflicts of interest. Ethics Approval Statement: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The project was approved by the Research Ethics Board of each of the participating institutions. All participants provided informed consent.
- Published
- 2021
23. Evaluation of LAMP for detection of Shigella from stool samples in children
- Author
-
Nandini Dendukuri, Subramanian Mahadevan, Jharna Mandal, Sitanshu Sekhar Kar, Ramya Raghavan, Shouao Wang, and Barath Jagadisan
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Genomic sequencing ,030106 microbiology ,Prevalence ,Loop-mediated isothermal amplification ,Dysentery ,Diagnostic accuracy ,medicine.disease ,medicine.disease_cause ,01 natural sciences ,Gastroenterology ,010104 statistics & probability ,03 medical and health sciences ,Internal medicine ,Watery diarrhoea ,Medicine ,General Materials Science ,Shigella ,0101 mathematics ,business ,Reference standards - Abstract
Background. To assess the diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for the detection of Shigella from stool samples from children. Methods. Consecutive stool samples from children aged Results. Amongst the 374 stool samples tested, 291 samples were positive by LAMP and 213 were positive by the composite reference standard. The sensitivity of LAMP was 100 % (98.3–100 %) and its specificity was 51.6 % (43.6–59.5 %) with a disease prevalence of 57 %. The sensitivity and specificity of LAMP improved to 99.3 % (94.2–100) and 98.2 % (94.5–99.9), respectively, using latent class analysis, while assuming that genomic sequencing has perfect specificity. Discussion. The authors have standardized the LAMP procedure for direct application to clinical stool samples. LAMP is a sensitive and specific method for the diagnosis of Shigella from stool samples of children as compared to both culture and conventional PCR.
- Published
- 2020
24. Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis
- Author
-
Nandini Dendukuri, Ian Schiller, Mikashmi Kohli, Adrienne E Shapiro, Karen R Steingart, David J. Horne, and Jennifer M. Ross
- Subjects
medicine.medical_specialty ,education.field_of_study ,Tuberculosis ,business.industry ,Population ,Human immunodeficiency virus (HIV) ,Rifampicin resistance ,bacterial infections and mycoses ,medicine.disease_cause ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Pulmonary tuberculosis ,Internal medicine ,Primary health ,medicine ,wf_220 ,Pharmacology (medical) ,wf_200 ,030212 general & internal medicine ,education ,business ,wf_300 ,030217 neurology & neurosurgery - Abstract
Objectives\ud This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:\ud \ud To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for tuberculosis in adults irrespective of signs or symptoms of pulmonary tuberculosis in the general population (i.e. low‐risk population).\ud \ud To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening of pulmonary tuberculosis in adults in the following high‐risk groups.\ud \ud People living with HIV.\ud \ud Household contacts of people with tuberculosis.\ud \ud Patients residing in high‐tuberculosis‐burden settings attending primary health facilities.\ud \ud Homeless people.\ud \ud Miners.\ud \ud People with diabetes mellitus.\ud \ud People who abuse alcohol.\ud \ud Smokers.\ud \ud People residing in prisons.\ud \ud Healthcare workers.\ud \ud To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the detection of rifampicin resistance in the general population and in the high‐risk groups and settings described above.\ud \ud Secondary objectives\ud To compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the above high‐risk groups and settings.\ud \ud To investigate potential sources of heterogeneity in accuracy estimates, including the percentage of participants with tuberculosis symptoms, tuberculosis burden, tuberculosis/HIV burden, and MDR‐TB burden.
- Published
- 2020
25. International Survey on Determinants of Antibiotic Duration and Discontinuation in Pediatric Critically Ill Patients
- Author
-
Milagros Gonzales, Lalida Kongkiattikul, Kim C. Noël, Atsushi Kawaguchi, Jacques Lacroix, Fabrizio Chiusolo, Jesse Papenburg, Steven Reynolds, Shauna O'Donnell, James Dayre McNally, Yasser M. Kazzaz, Caroline Quach, Masanori Sato, Patricia S. Fontela, François Dubos, Stéphane Leteurtre, Yasemin Karaca, Nandini Dendukuri, Douglas F. Willson, Elaine Gilfoyle, and Jefferson Pedro Piva
- Subjects
medicine.medical_specialty ,Canada ,Cross-sectional study ,medicine.drug_class ,Critical Illness ,Antibiotics ,Psychological intervention ,MEDLINE ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,Surveys and Questionnaires ,medicine ,Humans ,Child ,business.industry ,Septic shock ,030208 emergency & critical care medicine ,medicine.disease ,United States ,Discontinuation ,Anti-Bacterial Agents ,Pneumonia ,Cross-Sectional Studies ,Italy ,Pediatrics, Perinatology and Child Health ,France ,business ,Meningitis ,Brazil - Abstract
Objectives We hypothesized that antibiotic use in PICUs is based on criteria not always supported by evidence. We aimed to describe determinants of empiric antibiotic use in PICUs in eight different countries. Design Cross-sectional survey. Setting PICUs in Canada, the United States, France, Italy, Saudi Arabia, Japan, Thailand, and Brazil. Subjects Pediatric intensivists. Interventions None. Measurements and main results We used literature review and focus groups to develop the survey and its clinical scenarios (pneumonia, septic shock, meningitis, and intra-abdominal infections) in which cultures were unreliable due to antibiotic pretreatment. Data analyses included descriptive statistics and linear regression with bootstrapped SEs. Overall response rate was 39% (482/1,251), with individual country response rates ranging from 25% to 76%. Respondents in all countries prolonged antibiotic duration based on patient characteristics, disease severity, pathogens, and radiologic findings (from a median increase of 1.8 d [95% CI, 0.5-4.0 d] to 9.5 d [95% CI, 8.5-10.5 d]). Younger age, severe disease, and ventilator-associated pneumonia prolonged antibiotic treatment duration despite a lack of evidence for such practices. No variables were reported to shorten treatment duration for all countries. Importantly, more than 39% of respondents would use greater than or equal to 7 days of antibiotics for patients with a positive viral polymerase chain reaction test in all scenarios, except in France for pneumonia (29%), septic shock (13%), and meningitis (6%). The use of elevated levels of inflammatory markers to prolong antibiotic treatment duration varied among different countries. Conclusions Antibiotic-related decisions are complex and may be influenced by cultural and contextual factors. Evidence-based criteria are necessary to guide antibiotic duration and ensure the rational use of antibiotics in PICUs.
- Published
- 2020
26. Accuracy of Blood Cultures and Molecular Diagnostics in Intensive Care Units to Diagnose Sepsis: A Bayesian Latent Class Model Analysis
- Author
-
Sriram Sampath, Nandini Dendukuri, Jeswin Baby, Tinku Thomas, and Bhuvana Krishna
- Subjects
medicine.medical_specialty ,Diagnostic methods ,business.industry ,Bayesian probability ,Gold standard (test) ,Molecular diagnostics ,medicine.disease ,Intensive care unit ,Latent class model ,law.invention ,Sepsis ,law ,Intensive care ,Emergency medicine ,medicine ,business - Abstract
Background: Confirmation of sepsis by Standard blood cultures(STD) is often inconclusive due to slow growth and low positivity. Molecular diagnostics (MOL) are faster and may have higher positivity, but test performance can be inaccurately estimated if STD methods are used as comparators.Bayesian Latent class models(LCMs) can evaluate diagnostic methods when there is no “gold standard”. Intensive Care Unit studies which have used LCMs to combine and compare STD and MOL method performance, and estimate prevalence of sepsis have not been described. Methods: Results from an ICU sepsis study which used both tests were analyzed. Bayesian LCMs combined prior prevalences of sepsis, diagnostic characteristics of the two methods ,and the study results to estimate posterior prevalence and diagnostic characteristics.Sensitivity analyses were performed by using varying objective and subjective prior parameters. Positive predictive values(PPVs) of the prevalence of sepsis were estimated for all combinations of test results. Finding: Posterior estimates were: sepsis prevalence(0·38–0·88), sensitivities(STD:0·2–0·35,MOL: 0·56–0·86) and specificities(STD:0·87–0·99,MOL:0·72–0·95) . The PPV (sepsis) of both tests being positive was (0·72–0·99). Interpretation: LCMs combined two imperfect methods to estimate prevalence,PPV, and diagnostic characteristics. The posterior estimates (STD sensitivity and STD specificity) seem to reflect clinical experience appropriately. The high PPV when both methods show positive results can be useful for ruling in disease. Funding Statement: This study has not received any funding from any source. Declaration of Interests: We declare no competing interests. Ethics Approval Statement: This study had recruited patients from the ICU of St John’s Medical College, Bangalore from April 2010 to September 2010 after Institutional Ethical Committee approval (IEC: Ref-188/2008). Further consent for performance of this study was also obtained (IEC: Ref-002/2020).
- Published
- 2020
27. Immediate Versus Delayed Stenting in Patients with Acute ST-Elevation Myocardial Infarction: A Randomized Open-Label Bayesian Trial
- Author
-
Thomas Engstrøm, Nicolas Delarche, Erick Schampaert, Cheol Woong Yu, Michael McGillion, Nandini Dendukuri, Patrick Bélisle, X. Marcaggi, Géraud Souteyrand, Colin Berry, Guillaume Cayla, E. Marc Jolicoeur, François Roubille, Simon Kouz, Dan Eik Høfsten, Henning Kelbæk, Samer Mansour, Brahim Harbaoui, Grégoire Rangé, Loic Belle, Gilles Zemour, Frédéric Bouisset, James M. Brophy, Lars Køber, David Carrick, and Ziad Boueri
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Declaration ,medicine.disease ,law.invention ,Randomized controlled trial ,law ,Angioplasty ,Relative risk ,Emergency medicine ,Clinical endpoint ,medicine ,Data monitoring committee ,In patient ,Myocardial infarction ,business - Abstract
Background: Stents immediately implanted in thrombus-laden arteries cause embolization, which paradoxically impairs myocardial reperfusion and function. Methods: We conducted a Bayesian open-label randomized trial across 15 centres in France and Canada. Patients with acute ST-elevation myocardial infarction (STEMI) and reperfused by thrombectomy or small-size balloon angioplasty were randomly assigned to immediate stenting or to a bridging anti-thrombin therapy and delayed stenting between 18h to 48h after reperfusion. Using a hierarchical Bayesian analysis, we borrowed data from exchangeable twin trials to form a posterior probability of the risk ratio (RR) for the combined occurrence of cardiovascular death, heart failure, non-fatal myocardial infarction (MI), or target-vessel revascularisation (TVR) over 9 months in the intent-to-treat populations. Findings: Between April 2014 and September 2017, 305 participants were randomly assigned to delayed (n = 152) or immediate stenting (n = 153). In parallel, four similar RCTs were reported that satisfied exchangeability requirements, leading to 1,873 participants, including 930 assigned to delayed and 943 assigned to immediate stenting. The primary endpoint occurred in 167 participants (18.1%) assigned to delayed stenting compared to 194 participants (20.6%) assigned to immediate stenting (RR, 0.91; 95% credible interval [95%CrI], 0.76 to 1.09; probability of superiority, 89%). Delayed stenting led to a meaningful increase in unplanned target revascularization acutely (RR, 1.54; 95% CrI, 0.98 to 2.41, probability of inferiority, 99%). At long term, delayed stenting reduced the combined occurrence of CV death or heart failure (RR, 0.83; 95% CrI, 0.67 to 1.02, probability of superiority, 99%). Interpretation: In patients with STEMI, delayed stenting did not reduce the occurrence of cardiovascular death, non-fatal MI, heart failure and unplanned TVR compared to the immediate stenting. There is a high probability that delayed stenting substantially reduces cardiovascular death and heart failure in the longer-term. Trial Registration: ClinicalTrials.gov identifier: NCT01542385. Funding Statement: The trial was supported by an operating grant from the peer-reviewed, publically funded Canadian Institute of Health Research (CIHR), through the Industry-Partnered Collaborative Research program (grant #298937), in collaboration with Boston Scientific and AstraZeneca (unrestricted grants support). The industry partners played no role in the conduct and oversight of the study. Declaration of Interests: The investigators disclose the following relationships: E. Marc Jolicoeur: Advisory Board: Institut National d’Excellence en Sante et Services Sociaux du Quebec, Servier, Imbria Pharmaceutical, Carre technology; Board of Directors, Societe de Sciences Vasculaires du Quebec; Data Safety Monitoring Board: XyloCor; Research grants; Boston Scientific, AstraZeneca; The University of Glasgow (employer, C Berry) holds research and/or consultancy agreements with AstraZeneca, Abbott Vascular, Boehringer Ingelheim, GSK, HeartFlow, Novartis and Siemens Healthcare; Francois Roubille: Advisory Board: Abbott, Air liquide, Research grants; Boston Scientific, AstraZeneca. Consultancy agreements with AstraZeneca, Abbott Vascular, Air liquide, Amgen, Boehringer Ingelheim, GSK, MSD, Novartis, Sanofi, Novartis, Novonordisk, Vifor; Geraud Souteyrand: Consultancy agreements; Medtronic, Abbott, and Terumo; Guillaume Cayla: Consultancy agreements; Astra Zeneca, Amgen, Abbot Vascular, BMS, Boston, Biotronik, Medtronic, Pfizer, and Sanofi; Nicolas Delarche: Advisory board: Novartis; Samer Mansour: Consultant/Advisory board/Speaker’s Bureau: Abbott vascular, Soundbite, Boehringer Ingelheim, AstraZeneca, Bayer, BMS-Pfizer Alliance, Medtronic, Amgen, Sanofi, Servier, Gilead and Novartis; Erick Schampaert: Consultant/Advisory board/Speaker’s Bureau: Abbott, AstraZeneca, Bayer, BMS-Pfizer Alliance, Medtronic, Philips-Volcano, Servier; Loic Belle: Research Grant: AstraZeneca, Medtronic, Biotronic, Boston Scientific, Abbott Vascular, Terumo Ethics Approval Statement: The protocol complied with the Declaration of Helsinki and was approved by IRB at each participating centers. The trial was coordinated by the Montreal Health Innovation Coordinating Centre under the direction of the executive committee, which was responsible for trial conduct, the integrity of the data analysis, and the reporting of results.
- Published
- 2020
28. Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial
- Author
-
Lars Køber, Thomas Engstrøm, Grégoire Rangé, Patrick Bélisle, E. Marc Jolicoeur, Nicolas Delarche, Brahim Harbaoui, Colin Berry, David Carrick, Michael McGillion, Jean-François Tanguay, Géraud Souteyrand, Frédéric Bouisset, François Roubille, Simon Kouz, Samer Mansour, Jean-Claude Tardif, Dan Eik Høfsten, Guillaume Cayla, James M. Brophy, Erick Schampaert, Cheol Woong Yu, Gilles Zemour, Loic Belle, Nandini Dendukuri, Henning Kelbæk, X. Marcaggi, Ziad Boueri, MORNET, Dominique, Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada., Centre for Outcomes Research, McGill University Health Centre-Research Institute, Montreal, Quebec, Canada, HOPITAL CHARTRES - DEPT CARDIOL, Montreal Health Innovation Coordination Center, Montreal, Quebec, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier de Cannes (Centre Hospitalier de Cannes), Centre Hospitalier de Cannes, Centre hospitalier de Pau, Imagerie Ultrasonore, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hopital Sacre-Coeur, Interventional Cardiology, Université de Montréal, Montreal, Quebec, Centre Hospitalier Régional de Lanaudiere [Joliette, QC, Canada] (CHRDL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de Bastia, Ctr Hosp Vichy, Montreal Heart Institute Coordinating Centre (MHICC), Université de Montréal (UdeM), Montreal Heart Institute - Institut de Cardiologie de Montréal, Department of Cardiology, Gentofte University Hospital, Rigshospitalet [Copenhagen], Copenhagen University Hospital, Service de Cardiologie, Centre hospitalier de la région d'Annecy, Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional de Lanaudiere, Joliette, Quebec, and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,030204 cardiovascular system & hematology ,Prosthesis Design ,law.invention ,Time-to-Treatment ,03 medical and health sciences ,0302 clinical medicine ,Percutaneous Coronary Intervention ,Randomized controlled trial ,law ,St elevation myocardial infarction ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,ComputingMilieux_MISCELLANEOUS ,Randomized Controlled Trials as Topic ,business.industry ,Antithrombin ,Stent ,Percutaneous coronary intervention ,Bayes Theorem ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,surgical procedures, operative ,medicine.anatomical_structure ,Heart failure ,Cardiology ,ST Elevation Myocardial Infarction ,Stents ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Artery - Abstract
Background Primary percutaneous coronary intervention is used to restore blood flow in the infarct-related coronary artery, followed by immediate stenting to prevent reocclusion. Stents implanted in thrombus-laden arteries cause distal embolization, which paradoxically impairs myocardial reperfusion and ventricular function. Whether a strategy of delayed stenting improves outcomes in patients with acute ST-elevation myocardial infarction (STEMI) is uncertain. Methods The Primary Reperfusion Secondary Stenting (PRIMACY) is a Bayesian prospective, randomized, open-label, blinded end point trial in which delayed vs immediate stenting in patients with STEMI were compared for prevention of cardiovascular death, nonfatal myocardial infarction, heart failure, or unplanned target vessel revascularization at 9 months. All participants were immediately reperfused, but those assigned to the delayed arm underwent stenting after an interval of 24 to 48 hours. This interval was bridged with antithrombin therapy to reduce thrombus burden. In the principal Bayesian hierarchical random effects analysis, data from exchangeable trials will be combined into a study prior and updated with PRIMACY into a posterior probability of efficacy. Results A total of 305 participants were randomized across 15 centres in France and Canada between April 2014 and September 2017. At baseline, the median age of participants was 59 years, 81% were male, and 3% had a history of percutaneous coronary intervention. Results from PRIMACY will be updated from the patient-level data of 1568 participants enrolled in the Deferred Stent Trial in STEMI (DEFER; United Kingdom), Minimalist Immediate Mechanical Intervention (MIMI; France), Danish Trial in Acute Myocardial Infarction-3 (DANAMI-3; Denmark), and Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST Segment–Elevation Myocardial Infarction (INNOVATION, South Korea) trials. Conclusions We expect to clarify whether delayed stenting can safely reduce the occurrence of adverse cardiovascular end points compared with immediate stenting in patients with STEMI.
- Published
- 2020
29. Multiplex Respiratory Virus Testing for Antimicrobial Stewardship: A Prospective Assessment of Antimicrobial Use and Clinical Outcomes Among Hospitalized Adults
- Author
-
Vivian G. Loo, Makeda Semret, Barbara Ann Jardin, Nandini Dendukuri, Jesse Papenburg, Ian Schiller, Shelly A. McNeil, and Charles Frenette
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Pediatrics ,medicine.drug_class ,viruses ,030106 microbiology ,Antibiotics ,Orthomyxoviridae ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Immunology and Allergy ,Antimicrobial stewardship ,030212 general & internal medicine ,Respiratory tract infections ,biology ,business.industry ,medicine.disease ,biology.organism_classification ,Antimicrobial ,3. Good health ,Pneumonia ,Infectious Diseases ,Respiratory virus ,business - Abstract
Background Respiratory tract infections are frequent causes of hospitalization and initiation of empirical antimicrobial therapy. Testing for a broad panel of respiratory viruses has been advocated as a useful tool for antibiotic stewardship. We conducted a prospective observational study to assess the impact of rapid viral test results on antimicrobial prescriptions and clinical outcomes among hospitalized adults. Methods Eight hundred patients admitted with respiratory symptoms were tested by a 12-virus respiratory panel (RVP) during 3 consecutive winters in Montreal, Canada. The primary outcome measure was change in antimicrobial prescriptions (ie, de-escalation of empirical antimicrobial therapy or commencement of new antimicrobial therapy) after RVP results were available. Clinical outcomes were also assessed. Results Influenza virus was identified in 53% of individuals in the study population, and other viruses were identified in 10%. Influenza virus positivity was associated with shorter duration of hospitalization and appropriate antiviral management. Antibiotic management was most significantly correlated with radiographic suspicion of pneumonia and less so with results of the RVP. Positivity for viruses other than influenza virus was not correlated with significantly different outcomes. Conclusions Physicians respond to results of testing for influenza virus when managing hospitalized adult patients but respond less to test results for other viruses. These data can inform the design of stewardship interventions and the selection of viral testing panels for hospitalized patients.
- Published
- 2017
- Full Text
- View/download PDF
30. Bayesian estimation of sensitivity and specificity of a milk pregnancy-associated glycoprotein-based ELISA and of transrectal ultrasonographic exam for diagnosis of pregnancy at 28–45 days following breeding in dairy cows
- Author
-
Jocelyn Dubuc, Simon Dufour, Shereen Hassan, Jean Durocher, Nandini Dendukuri, and Sébastien Buczinski
- Subjects
Pregnancy Tests ,040301 veterinary sciences ,Pregnancy associated glycoprotein ,Enzyme-Linked Immunosorbent Assay ,Breeding ,Sensitivity and Specificity ,Ultrasonography, Prenatal ,0403 veterinary science ,Food Animals ,Pregnancy ,Statistics ,Covariate ,medicine ,Animals ,Longitudinal Studies ,Dairy cattle ,Glycoproteins ,Bayes estimator ,Conditional dependence ,business.industry ,Quebec ,0402 animal and dairy science ,Bayes Theorem ,04 agricultural and veterinary sciences ,Gold standard (test) ,medicine.disease ,040201 dairy & animal science ,Latent class model ,Dairying ,Parity ,Milk ,Cattle ,Female ,Animal Science and Zoology ,business - Abstract
Using a milk sample for pregnancy diagnosis in dairy cattle is extremely convenient due to the low technical inputs required for collection of biological materials. Determining accuracy of a novel pregnancy diagnostic test that relies on a milk sample is, however, difficult since no gold standard test is available for comparison. The objective of the current study was to estimate diagnostic accuracy of the milk PAG-based ELISA and of transrectal ultrasonographic (TUS) exam for determining pregnancy status of individual dairy cows using a methodology suited for test validation in the absence of gold standard. Secondary objectives were to evaluate whether test accuracy varies with cow's characteristics and to identify the optimal ELISA optical density threshold for PAG test interpretation. Cows (n=519) from 18 commercial dairies tested with both TUS and PAG between 28 and 45days following breeding were included in the study. Other covariates (number of days since breeding, parity, and daily milk production) hypothesized to affect TUS or PAG test accuracy were measured. A Bayesian hierarchical latent class model (LCM) methodology assuming conditional independence between tests was used to obtain estimates of tests' sensitivities (Se) and specificities (Sp), to evaluate impact of covariates on these, and to compute misclassification costs across a range of ELISA thresholds. Very little disagreement was observed between tests with only 23 cows yielding discordant results. Using the LCM model with non-informative priors for tests accuracy parameters, median (95% credibility intervals [CI]) TUS Se and Sp estimates of 0.96 (0.91, 1.00) and 0.99 (0.97, 1.0) were obtained. For the PAG test, median (95% CI) Se of 0.99 (0.98, 1.00) and Sp of 0.95 (0.89, 1.0) were observed. The impact of adjusting for conditional dependence between tests was negligible. Test accuracy of the PAG test varied slightly by parity number. When assuming false negative to false positive costs ratio≥3:1, the optimal ELISA optical density threshold allowing minimization of misclassification costs was 0.25. In conclusion, both TUS and PAG showed excellent accuracy for pregnancy diagnosis in dairy cows. When using the PAG test, a threshold of 0.25 could be used for test interpretation.
- Published
- 2017
31. Latent Class Analysis and the Need for Clear Reporting of Methods
- Author
-
Emily MacLean and Nandini Dendukuri
- Subjects
Microbiology (medical) ,Tuberculin Test ,business.industry ,bacterial infections and mycoses ,computer.software_genre ,Diagnostic test evaluation ,Latent class model ,Infectious Diseases ,Latent Class Analysis ,Latent Tuberculosis ,Humans ,Medicine ,Artificial intelligence ,Online Only Articles ,business ,computer ,Natural language processing - Abstract
BACKGROUND: Increased risk of progression from latent tuberculosis infection (LTBI) to tuberculosis (TB) disease among people living with human immunodeficiency virus (HIV; PLWH) prioritizes them for LTBI testing and treatment. Studies comparing the performance of interferon gamma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking. METHODS: We used Bayesian latent class analysis to estimate the prevalence of LTBI and diagnostic characteristics of the TST, QuantiFERON Gold In-Tube (QFT), and T.SPOT-TB (TSPOT) among a prospective, multicenter cohort of US-born PLWH ≥5 years old with valid results for all 3 LTBI tests using standard US cutoffs (≥5 mm TST, ≥0.35 IU/mL QFT, ≥8 spots TSPOT). We also explored the performance of varying LTBI test cutoffs. RESULTS: Among 1510 PLWH (median CD4+ count 532 cells/mm(3)), estimated LTBI prevalence was 4.7%. TSPOT was significantly more specific (99.7%) and had a significantly higher positive predictive value (90.0%, PPV) than QFT (96.5% specificity, 50.7% PPV) and TST (96.8% specificity, 45.4% PPV). QFT was significantly more sensitive (72.2%) than TST (54.2%) and TSPOT (51.9%); negative predictive value of all tests was high (TST 97.7%, QFT 98.6%, TSPOT 97.6%). Even at the highest cutoffs evaluated (15 mm TST, ≥1.00 IU/mL QFT, ≥8 spots TSPOT), TST and QFT specificity was significantly lower than TSPOT. CONCLUSIONS: LTBI prevalence among this cohort of US-born PLWH was low compared to non-US born persons. TSPOT’s higher PPV may make it preferable for testing US-born PLWH at low risk for TB exposure and with high CD4+ counts.
- Published
- 2020
32. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV
- Author
-
Mikashmi Kohli, Nandini Dendukuri, Stephanie Bjerrum, Alice Zwerling, Ian Schiller, Claudia M. Denkinger, Ruvandhi R. Nathavitharana, Maunank Shah, and Karen R Steingart
- Subjects
Medicine General & Introductory Medical Sciences ,mesh:Tuberculosis, Pulmonary ,medicine.medical_specialty ,mesh:Point‐of‐Care Systems ,Tuberculosis ,Population ,mesh:Biomarkers ,mesh:Tuberculosis ,mesh:Sensitivity and Specificity ,mesh:HIV Seropositivity/complications ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Tuberculosis diagnosis ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,education ,mesh:Tuberculosis/diagnosis ,education.field_of_study ,Lipoarabinomannan ,business.industry ,mesh:Lipopolysaccharides ,medicine.disease ,mesh:Randomized Controlled Trials as Topic ,mesh:HIV Seropositivity ,mesh:Tuberculosis, Pulmonary/diagnosis ,3. Good health ,Clinical trial ,mesh:Biomarkers/urine ,mesh:Humans ,Sputum ,mesh:Adult ,mesh:CD4 Lymphocyte Count ,medicine.symptom ,business ,mesh:Lipopolysaccharides/urine ,030217 neurology & neurosurgery ,Cohort study - Abstract
Background The lateral flow urine lipoarabinomannan (LF‐LAM) assay Alere Determine™ TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active tuberculosis in HIV‐positive people with severe HIV disease. This review update asks the question, "does new evidence justify the use of LF‐LAM in a broader group of people?”, and is part of the WHO process for updating guidance on the use of LF‐LAM. Objectives To assess the accuracy of LF‐LAM for the diagnosis of active tuberculosis among HIV‐positive adults with signs and symptoms of tuberculosis (symptomatic participants) and among HIV‐positive adults irrespective of signs and symptoms of tuberculosis (unselected participants not assessed for tuberculosis signs and symptoms). The proposed role for LF‐LAM is as an add on to clinical judgement and with other tests to assist in diagnosing tuberculosis. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register; MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, without language restriction to 11 May 2018. Selection criteria Randomized trials, cross‐sectional, and observational cohort studies that evaluated LF‐LAM for active tuberculosis (pulmonary and extrapulmonary) in HIV‐positive adults. We included studies that used the manufacturer's recommended threshold for test positivity, either the updated reference card with four bands (grade 1 of 4) or the corresponding prior reference card grade with five bands (grade 2 of 5). The reference standard was culture or nucleic acid amplification test from any body site (microbiological). We considered a higher quality reference standard to be one in which two or more specimen types were evaluated for tuberculosis diagnosis and a lower quality reference standard to be one in which only one specimen type was evaluated. Data collection and analysis Two review authors independently extracted data using a standardized form and REDCap electronic data capture tools. We appraised the quality of studies using the Quality Assessment of Diagnostic Accuracy Studies‐2 (QUADAS‐2) tool and performed meta‐analyses to estimate pooled sensitivity and specificity using a bivariate random‐effects model and a Bayesian approach. We analyzed studies enrolling strictly symptomatic participants separately from those enrolling unselected participants. We investigated pre‐defined sources of heterogeneity including the influence of CD4 count and clinical setting on the accuracy estimates. We assessed the certainty of the evidence using the GRADE approach. Main results We included 15 unique studies (nine new studies and six studies from the original review that met the inclusion criteria): eight studies among symptomatic adults and seven studies among unselected adults. All studies were conducted in low‐ or middle‐income countries. Risk of bias was high in the patient selection and reference standard domains, mainly because studies excluded participants unable to produce sputum and used a lower quality reference standard. Participants with tuberculosis symptoms LF‐LAM pooled sensitivity (95% credible interval (CrI) ) was 42% (31% to 55%) (moderate‐certainty evidence) and pooled specificity was 91% (85% to 95%) (very low‐certainty evidence), (8 studies, 3449 participants, 37% with tuberculosis). For a population of 1000 people where 300 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 189 to be LF‐LAM positive: of these, 63 (33%) would not have tuberculosis (false‐positives); and 811 to be LF‐LAM negative: of these, 174 (21%) would have tuberculosis (false‐negatives). By clinical setting, pooled sensitivity was 52% (40% to 64%) among inpatients versus 29% (17% to 47%) among outpatients; and pooled specificity was 87% (78% to 93%) among inpatients versus 96% (91% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity increased, and specificity decreased with lower CD4 cell count. Unselected participants not assessed for signs and symptoms of tuberculosis LF‐LAM pooled sensitivity was 35% (22% to 50%), (moderate‐certainty evidence) and pooled specificity was 95% (89% to 96%), (low‐certainty evidence), (7 studies, 3365 participants, 13% with tuberculosis). For a population of 1000 people where 100 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 80 to be LF‐LAM positive: of these, 45 (56%) would not have tuberculosis (false‐positives); and 920 to be LF‐LAM negative: of these, 65 (7%) would have tuberculosis (false‐negatives). By clinical setting, pooled sensitivity was 62% (41% to 83%) among inpatients versus 31% (18% to 47%) among outpatients; pooled specificity was 84% (48% to 96%) among inpatients versus 95% (87% to 99%) among outpatients. Stratified by CD4 cell count, pooled sensitivity increased, and specificity decreased with lower CD4 cell count. Authors' conclusions We found that LF‐LAM has a sensitivity of 42% to diagnose tuberculosis in HIV‐positive individuals with tuberculosis symptoms and 35% in HIV‐positive individuals not assessed for tuberculosis symptoms, consistent with findings reported previously. Regardless of how people are enrolled, sensitivity is higher in inpatients and those with lower CD4 cell, but a concomitant lower specificity. As a simple point‐of‐care test that does not depend upon sputum evaluation, LF‐LAM may assist with the diagnosis of tuberculosis, particularly when a sputum specimen cannot be produced., Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV Why is improving the diagnosis of tuberculosis important? Tuberculosis causes more deaths in people living with HIV than any other disease. The lateral flow urine lipoarabinomannan assay (LF‐LAM, Alere Determine™ TB LAM Ag assay) is a World Health Organization‐recommended rapid test to assist in detection of active tuberculosis in HIV‐positive people with severe HIV disease. Rapid and early tuberculosis diagnosis may allow for prompt treatment and alleviate severe illness and death. An incorrect tuberculosis diagnosis may result in anxiety and unnecessary treatment. What is the aim of this review? To find out how accurate LF‐LAM is for diagnosing tuberculosis in HIV‐positive people with tuberculosis symptoms (symptomatic participants) and those not assessed for tuberculosis symptoms (unselected participants). This is an update of the 2016 Cochrane Review. What was studied in this review? LF‐LAM is a commercially available point‐of‐care test that detects lipoarabinomannan (LAM), a component of the bacterial cell walls, present in some people with active tuberculosis. The test is simple and shows results in 25 minutes. LF‐LAM results were measured against culture or molecular tests (benchmark). What are the main results of this review? Fifteen studies: eight studies evaluated LF‐LAM for tuberculosis among symptomatic participants and seven studies among unselected participants. All studies were conducted in low‐ or middle‐income countries. Tuberculosis diagnosis among symptomatic participants: LF‐LAM registered positive in 42% (sensitivity) of people who actually had tuberculosis and did not register positive in 91% of people who were actually negative (specificity). Tuberculosis diagnosis among unselected participants: LF‐LAM sensitivity was 35% and specificity 95%. How confident are we in the review’s results? Several studies excluded participants who could not produce sputum and most studies relied on a lower quality benchmark. Few studies and participants were included in some analyses and only one study was conducted outside of sub‐Saharan Africa. Results should be interpreted with caution. What do the results mean? Among symptomatic participants, in theory, for a population of 1000 people where 300 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 189 to be LF‐LAM positive: of these, 63 (33%) would not have tuberculosis (false‐positives); and 811 to be LF‐LAM negative: of these, 174 (21%) would have tuberculosis (false‐negatives). Among unselected participants, in theory, for a population of 1000 people where 100 have microbiologically‐confirmed tuberculosis, the utilization of LF‐LAM would result in: 80 to be LF‐LAM positive: of these, 45 (56%) would not have tuberculosis (false‐positives); and 920 to be LF‐LAM negative: of these, 65 (7%) would have tuberculosis (false‐negatives). Who do the review’s results apply to? HIV‐positive people with tuberculosis symptoms and those not assessed for tuberculosis symptoms. What are the implications of this review? LF‐LAM has sensitivity around 40% to detect tuberculosis. As the test does not require sputum collection, LF‐LAM may be the only way to diagnose tuberculosis when sputum cannot be produced. How up‐to‐date is this review? To 11 May 2018.
- Published
- 2019
33. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
- Author
-
Karen R Steingart, Deanna Tollefson, Jerry S Zifodya, David J. Horne, Samuel G Schumacher, Eleanor A Ochodo, Ian Schiller, Mikashmi Kohli, Madhukar Pai, and Nandini Dendukuri
- Subjects
mesh:Tuberculosis, Pulmonary ,Extensively Drug-Resistant Tuberculosis ,Antibiotics ,mesh:Mycobacterium tuberculosis ,mesh:Rifampin ,Rifampicin resistance ,Drug resistance ,0302 clinical medicine ,mesh:Mycobacterium tuberculosis/isolation & purification ,mesh:Mycobacterium tuberculosis/genetics ,polycyclic compounds ,Pharmacology (medical) ,030212 general & internal medicine ,False Negative Reactions ,mesh:Mycobacterium tuberculosis/drug effects ,biology ,mesh:Polymerase Chain Reaction ,3. Good health ,mesh:Rifampin/therapeutic use ,mesh:Humans ,wf_200 ,mesh:Adult ,Rifampin ,medicine.drug ,Medicine General & Introductory Medical Sciences ,mesh:Sequence Analysis, DNA/methods ,Tuberculosis ,medicine.drug_class ,mesh:Tuberculosis, Pulmonary/drug therapy ,Microbial Sensitivity Tests ,mesh:Sensitivity and Specificity ,Sensitivity and Specificity ,mesh:Antibiotics, Antitubercular/therapeutic use ,Mycobacterium tuberculosis ,03 medical and health sciences ,mesh:Drug Resistance, Bacterial ,Pulmonary tuberculosis ,mesh:Sequence Analysis, DNA ,Drug Resistance, Bacterial ,medicine ,Humans ,False Positive Reactions ,Diagnostic Errors ,mesh:Antibiotics, Antitubercular ,Antibiotics, Antitubercular ,Tuberculosis, Pulmonary ,business.industry ,Extrapulmonary tuberculosis ,biology.organism_classification ,medicine.disease ,bacterial infections and mycoses ,Virology ,mesh:Tuberculosis, Pulmonary/diagnosis ,qv_268 ,mesh:Polymerase Chain Reaction/methods ,business ,wf_300 ,030217 neurology & neurosurgery ,Rifampicin - Abstract
Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the newest version, are the only World Health Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in persons with signs and symptoms of tuberculosis, at lower health system levels. A previous Cochrane Review found Xpert MTB/RIF sensitive and specific for tuberculosis (Steingart 2014). Since the previous review, new studies have been published. We performed a review update for an upcoming WHO policy review. Objectives To determine diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive pulmonary tuberculosis (PTB) and for rifampicin resistance in adults with presumptive rifampicin‐resistant tuberculosis. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, to 11 October 2018, without language restriction. Selection criteria Randomized trials, cross‐sectional, and cohort studies using respiratory specimens that evaluated Xpert MTB/RIF, Xpert Ultra, or both against the reference standard, culture for tuberculosis and culture‐based drug susceptibility testing or MTBDRplus for rifampicin resistance. Data collection and analysis Four review authors independently extracted data using a standardized form. When possible, we also extracted data by smear and HIV status. We assessed study quality using QUADAS‐2 and performed meta‐analyses to estimate pooled sensitivity and specificity separately for tuberculosis and rifampicin resistance. We investigated potential sources of heterogeneity. Most analyses used a bivariate random‐effects model. For tuberculosis detection, we first estimated accuracy using all included studies and then only the subset of studies where participants were unselected, i.e. not selected based on prior microscopy testing. Main results We identified in total 95 studies (77 new studies since the previous review): 86 studies (42,091 participants) evaluated Xpert MTB/RIF for tuberculosis and 57 studies (8287 participants) for rifampicin resistance. One study compared Xpert MTB/RIF and Xpert Ultra on the same participant specimen. Tuberculosis detection Of the total 86 studies, 45 took place in high tuberculosis burden and 50 in high TB/HIV burden countries. Most studies had low risk of bias. Xpert MTB/RIF pooled sensitivity and specificity (95% credible Interval (CrI)) were 85% (82% to 88%) and 98% (97% to 98%), (70 studies, 37,237 unselected participants; high‐certainty evidence). We found similar accuracy when we included all studies. For a population of 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF‐positive and 18 (17%) would not have tuberculosis (false‐positives); 897 would be Xpert MTB/RIF‐negative and 15 (2%) would have tuberculosis (false‐negatives). Xpert Ultra sensitivity (95% confidence interval (CI)) was 88% (85% to 91%) versus Xpert MTB/RIF 83% (79% to 86%); Xpert Ultra specificity was 96% (94% to 97%) versus Xpert MTB/RIF 98% (97% to 99%), (1 study, 1439 participants; moderate‐certainty evidence). Xpert MTB/RIF pooled sensitivity was 98% (97% to 98%) in smear‐positive and 67% (62% to 72%) in smear‐negative, culture‐positive participants, (45 studies). Xpert MTB/RIF pooled sensitivity was 88% (83% to 92%) in HIV‐negative and 81% (75% to 86%) in HIV‐positive participants; specificities were similar 98% (97% to 99%), (14 studies). Rifampicin resistance detection Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) were 96% (94% to 97%) and 98% (98% to 99%), (48 studies, 8020 participants; high‐certainty evidence). For a population of 1000 people where 100 have rifampicin‐resistant tuberculosis, 114 would be positive for rifampicin‐resistant tuberculosis and 18 (16%) would not have rifampicin resistance (false‐positives); 886 would be would be negative for rifampicin‐resistant tuberculosis and four (0.4%) would have rifampicin resistance (false‐negatives). Xpert Ultra sensitivity (95% CI) was 95% (90% to 98%) versus Xpert MTB/RIF 95% (91% to 98%); Xpert Ultra specificity was 98% (97% to 99%) versus Xpert MTB/RIF 98% (96% to 99%), (1 study, 551 participants; moderate‐certainty evidence). Authors' conclusions We found Xpert MTB/RIF to be sensitive and specific for diagnosing PTB and rifampicin resistance, consistent with findings reported previously. Xpert MTB/RIF was more sensitive for tuberculosis in smear‐positive than smear‐negative participants and HIV‐negative than HIV‐positive participants. Compared with Xpert MTB/RIF, Xpert Ultra had higher sensitivity and lower specificity for tuberculosis and similar sensitivity and specificity for rifampicin resistance (1 study). Xpert MTB/RIF and Xpert Ultra provide accurate results and can allow rapid initiation of treatment for multidrug‐resistant tuberculosis., Xpert MTB/RIF and Xpert Ultra for diagnosing pulmonary tuberculosis and rifampicin resistance in adults Why is improving the diagnosis of pulmonary tuberculosis important? Tuberculosis causes more deaths globally than any other infectious disease. When detected early and effectively treated, tuberculosis is largely curable, but in 2017, around 1.6 million people died of tuberculosis. Xpert MTB/RIF and Xpert Ultra, the newest version, are World Health Organization‐recommended tests that simultaneously detect tuberculosis and rifampicin resistance in persons with tuberculosis symptoms. Rifampicin is an important anti‐tuberculosis drug. Not recognizing tuberculosis early may result in delayed diagnosis and treatment, severe illness, and death. An incorrect tuberculosis diagnosis may result in anxiety and unnecessary treatment. What is the aim of this review? To determine how accurate Xpert MTB/RIF and Xpert Ultra are for diagnosing pulmonary tuberculosis (PTB) and rifampicin resistance in adults. This is an update of the 2014 Cochrane Review. What was studied in this review? Xpert MTB/RIF and Xpert Ultra, with results measured against culture (benchmark). What are the main results in this review? 95 studies: 86 studies (42,091 participants) evaluated Xpert MTB/RIF for tuberculosis; 57 studies (8287 participants) for rifampicin resistance. One study compared Xpert Ultra and Xpert MTB/RIF. For PTB, Xpert MTB/RIF was sensitive (85%), registering positive in people who actually had tuberculosis, and specific (98%), i.e. it did not register positive in people who were actually negative. Xpert Ultra had higher sensitivity than Xpert MTB/RIF (88% versus 83%) in one study. For rifampicin resistance, Xpert MTB/RIF was highly sensitive (96%) and specific (98%). Xpert Ultra gave similar results. Xpert MTB/RIF was better for diagnosing tuberculosis in HIV‐negative than in HIV‐positive people. How confident are we in the results of this review? Confident. We included many studies and used the best reference standards. Who do the results of this review apply to? People with presumed PTB or rifampicin resistance. What are the implications of this review? In theory, among 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF‐positive and 18 (17%) would not have tuberculosis (false‐positives); 897 would be Xpert MTB/RIF‐negative and 15 (2%) would have tuberculosis (false‐negatives). Among 1000 people where 100 have rifampicin resistance, 114 would be positive for rifampicin resistance and 18 (16%) would not have rifampicin resistance (false‐positives); 886 would be negative for rifampicin resistance and four (0.4%) would have rifampicin resistance (false‐negatives). How up‐to‐date is this review? To 11 October 2018.
- Published
- 2019
34. Accuracy of paratuberculosis diagnostic tests in small ruminants: protocol for a systematic review and meta-analysis
- Author
-
Nandini Dendukuri, Sébastien Buczinski, Julie Arsenault, Polychronis Kostoulas, F Corbière, Gilles Fecteau, Faculté de Médecine Vétérinaire [UdeM-Saint-Hyacinthe] (FMV - UdeM), Université de Montréal (UdeM), University of Thessaly [Volos] (UTH), Faculty of Veterinary Medicine, Clinic of Obstetrics and Reproduction, Interactions hôtes-agents pathogènes [Toulouse] (IHAP), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, and McGill University = Université McGill [Montréal, Canada]
- Subjects
040301 veterinary sciences ,[SDV]Life Sciences [q-bio] ,Sheep Diseases ,Paratuberculosis ,Disease ,AVIUM SUBSP PARATUBERCULOSIS ,0403 veterinary science ,Animals ,Medicine ,SPECIFICITY ,Goat Diseases ,Sheep ,Diagnostic Tests, Routine ,business.industry ,Goats ,0402 animal and dairy science ,Diagnostic test ,food and beverages ,Ruminants ,04 agricultural and veterinary sciences ,medicine.disease ,040201 dairy & animal science ,3. Good health ,Mycobacterium avium subsp. paratuberculosis ,Infectious disease (medical specialty) ,Meta-analysis ,Immunology ,Animal Science and Zoology ,SENSITIVITY ,business ,DAIRY SHEEP - Abstract
Paratuberculosis is a worldwide infectious disease caused by Mycobacterium avium ssp. paratuberculosis (MAP). Various ruminant species can be affected by the disease, and the diagnosis of the disease is challenging in the absence of a gold standard test. The aim of this systematic review protocol is to determine the accuracy of the direct and indirect diagnostic tests for MAP infection with a special focus on sheep and goats.
- Published
- 2019
35. Efficacy of Educational Interventions in Improving Measures of Living-donor Kidney Transplantation Activity: A Systematic Review and Meta-analysis
- Author
-
Shaifali Sandal, Ahsan Alam, Taline Ekmekjian, Elena Guadagno, Nandini Dendukuri, and Shouao Wang
- Subjects
medicine.medical_specialty ,Tissue and Organ Procurement ,media_common.quotation_subject ,Psychological intervention ,030230 surgery ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Patient Education as Topic ,law ,medicine ,Living Donors ,Humans ,Kidney transplantation ,media_common ,Selection bias ,Transplantation ,business.industry ,Graft Survival ,medicine.disease ,Kidney Transplantation ,Confidence interval ,Transplant Recipients ,Meta-analysis ,Relative risk ,Physical therapy ,030211 gastroenterology & hepatology ,business - Abstract
BACKGROUND To address patient-level barriers to living-donor kidney transplantation (LDKT), centers have implemented educational interventions. Recently, some have highlighted several gaps in knowledge and lack of evidence of efficacy of these interventions. No review has synthesized the available data. METHODS We conducted a systematic review and meta-analysis of studies conducted to increase measures of LDKT. Outcomes of interest were LDKT rates, donor evaluation, donor contact/inquiry, total transplantation rates, and change in knowledge scores and pursuit behaviors. A literature search was conducted across 7 databases from inception until 2017. Educational interventions were a decision/teaching aid alone or with personalized sessions. Comparator was another intervention or nonspecific education. Random effects meta-analysis was performed to pool risk ratios (RRs) across studies. RESULTS Of the 1813 references, 15 met the inclusion criteria; 9 were randomized control trials. When compared with nonspecific education, interventions increased LDKT rates (RR = 2.54; 95% confidence interval [CI], 1.49-4.35), donor evaluation (RR = 3.82; 95% CI, 1.91-7.64), and donor inquiry/contact (RR = 2.41; 95% CI, 1.53-3.80), but not total transplants (RR = 1.24; 95% CI, 0.96-1.61). Significant increased mean knowledge scores postintervention was noted, and most showed favorable trends in pursuit behaviors. Quality across the studies was mixed and sometimes difficult to assess. The biggest limitations were small sample size, selection bias, and short follow-ups. CONCLUSIONS Educational interventions improve measures of LDKT activity; however, current literature is heterogeneous and at risk of selection bias. Prospective studies with diverse patient populations, longer follow-ups, and robust outcomes are needed to inform clinical practice.
- Published
- 2019
36. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis
- Author
-
Naomi R. Marmorstein, Tobias Atkin, Gabriella Gobbi, Andrea Cipriani, Sorayya Askari, Shouao Wang, Jill Boruff, Nancy E. Mayo, Tomasz Zytynski, Mark A. Ware, and Nandini Dendukuri
- Subjects
medicine.medical_specialty ,Adolescent ,Suicide, Attempted ,Anxiety ,Suicidal Ideation ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Young adult ,Psychiatry ,Suicidal ideation ,Depression (differential diagnoses) ,Original Investigation ,Cannabis ,Depressive Disorder, Major ,biology ,business.industry ,Mental Disorders ,Age Factors ,biology.organism_classification ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Mental Health ,Mood ,Adolescent Behavior ,Meta-analysis ,Hallucinogens ,Major depressive disorder ,Marijuana Use ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Importance Cannabis is the most commonly used drug of abuse by adolescents in the world. While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on mood and suicidality in young adulthood. Objective To provide a summary estimate of the extent to which cannabis use during adolescence is associated with the risk of developing subsequent major depression, anxiety, and suicidal behavior. Data Sources Medline, Embase, CINAHL, PsycInfo, and Proquest Dissertations and Theses were searched from inception to January 2017. Study Selection Longitudinal and prospective studies, assessing cannabis use in adolescents younger than 18 years (at least 1 assessment point) and then ascertaining development of depression in young adulthood (age 18 to 32 years) were selected, and odds ratios (OR) adjusted for the presence of baseline depression and/or anxiety and/or suicidality were extracted. Data Extraction and Synthesis Study quality was assessed using the Research Triangle Institute item bank on risk of bias and precision of observational studies. Two reviewers conducted all review stages independently. Selected data were pooled using random-effects meta-analysis. Main Outcomes and Measures The studies assessing cannabis use and depression at different points from adolescence to young adulthood and reporting the corresponding OR were included. In the studies selected, depression was diagnosed according to the third or fourth editions of Diagnostic and Statistical Manual of Mental Disorders or by using scales with predetermined cutoff points. Results After screening 3142 articles, 269 articles were selected for full-text review, 35 were selected for further review, and 11 studies comprising 23 317 individuals were included in the quantitative analysis. The OR of developing depression for cannabis users in young adulthood compared with nonusers was 1.37 (95% CI, 1.16-1.62; I2 = 0%). The pooled OR for anxiety was not statistically significant: 1.18 (95% CI, 0.84-1.67; I2 = 42%). The pooled OR for suicidal ideation was 1.50 (95% CI, 1.11-2.03; I2 = 0%), and for suicidal attempt was 3.46 (95% CI, 1.53-7.84, I2 = 61.3%). Conclusions and Relevance Although individual-level risk remains moderate to low and results from this study should be confirmed in future adequately powered prospective studies, the high prevalence of adolescents consuming cannabis generates a large number of young people who could develop depression and suicidality attributable to cannabis. This is an important public health problem and concern, which should be properly addressed by health care policy.
- Published
- 2019
37. Predictors of discordant latent tuberculosis infection test results amongst South African health care workers
- Author
-
Roslynn Baatjies, Nandini Dendukuri, Rodney Ehrlich, Shahieda Adams, Zhuoyu Wang, and Keertan Dheda
- Subjects
Adult ,Male ,medicine.medical_specialty ,Health Personnel ,Population ,Tuberculin ,Black People ,Sensitivity and Specificity ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,South Africa ,0302 clinical medicine ,Medical microbiology ,Sensitivity ,Latent Tuberculosis ,Predictive Value of Tests ,Health care ,medicine ,Humans ,Mass Screening ,Discordance and health care worker ,lcsh:RC109-216 ,False Positive Reactions ,Latent tuberculosis infection ,030212 general & internal medicine ,education ,Aged ,0303 health sciences ,education.field_of_study ,Latent tuberculosis ,030306 microbiology ,business.industry ,Tuberculin Test ,Middle Aged ,medicine.disease ,Prognosis ,bacterial infections and mycoses ,Confidence interval ,3. Good health ,Test (assessment) ,Infectious Diseases ,Tropical medicine ,Specificity ,Female ,business ,Interferon-gamma Release Tests ,Demography ,Research Article - Abstract
Background The tuberculin skin test (TST) and interferon-gamma-release-assays (IGRAs) are utilized in screening programmes for presumed latent tuberculosis infection (LTBI) in health care workers (HCWs). However, inter-test comparison yields high rates of discordance, which is poorly understood. The aim of the study was therefore to identify factors associated with discordance amongst HCWs in a TB and HIV endemic setting. Methods 505 HCWs were screened for LTBI in South Africa using the TST and two IGRA assays (QuantiFERON-TB-Gold-In-Tube (QFT-GIT) and TSPOT.TB). Factors associated with discordance were analyzed using a multinomial logistic regression model. Results TST-IGRA discordance was negatively associated with longer duration of employment for both TSPOT.TB (OR = 0.92; 95% confidence interval (CI) 0.85–0.99) and QFT-GIT (OR = 0.90; 95% CI 0.84–0.96). Marked test discordance occurred in HIV-infected individuals who were more likely to have TSPOT.TB + ve / TST-ve discordance (OR 4.44; 95% CI 1.14–17.27) or TSPOT.TB + ve / QFT-GIT-ve test discordance (OR 5.72; 95% CI 1.95–16.78). Those engaged in home care were less likely to have QFT-GIT + ve/TSPOT.TB -ve / discordance (OR 0.32; 95% CI 0.10–0.95). Conclusion The marked TST-IGRA and IGRA-IGRA discordance in HIV-infected individuals suggest greater sensitivity of TSPOT.TB in immunocompromised persons or potential greater reactivity of TSPOT.TB in this population.
- Published
- 2019
38. Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway
- Author
-
Barry Stein, Patrick Charlebois, Nadia Safa, Juan Mata, Mohsen Alhashemi, Nicolò Pecorelli, Nandini Dendukuri, Julio F. Fiore, Liane S. Feldman, Franco Carli, Gabriele Baldini, A. Sender Liberman, Mohammed Al Mahroos, Alhashemi, M., Fiore, J. F., Safa, N., Al Mahroos, M., Mata, J., Pecorelli, N., Baldini, G., Dendukuri, N., Stein, B. L., Liberman, A. S., Charlebois, P., Carli, F., and Feldman, L. S.
- Subjects
Male ,medicine.medical_specialty ,Postoperative ileus ,Blood Loss, Surgical ,Context (language use) ,030230 surgery ,03 medical and health sciences ,Colonic Diseases ,0302 clinical medicine ,Ileus ,Postoperative Complications ,Enhanced recovery ,Risk Factors ,Internal medicine ,medicine ,Humans ,Colorectal ,Digestive System Surgical Procedures ,Aged ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Incidence ,Bayes Theorem ,Hepatology ,Middle Aged ,Colorectal surgery ,Analgesia, Epidural ,Analgesics, Opioid ,Rectal Diseases ,Critical Pathways ,Defecation ,Fluid Therapy ,030211 gastroenterology & hepatology ,Surgery ,Female ,Laparoscopy ,business ,Abdominal surgery - Abstract
Background: Prolonged postoperative ileus (PPOI) is common after colorectal surgery but has not been widely studied in the context of enhanced recovery pathways (ERPs) that include interventions aimed to accelerate gastrointestinal recovery. The aim of this study is to estimate the incidence and predictors of PPOI in the context of an ERP for colorectal surgery. Methods: We analyzed data from an institutional colorectal surgery ERP registry. Incidence of PPOI was estimated according to a definition adapted from Vather (intolerance of solid food and absence of flatus or bowel movement for ≥ 4days) and compared to other definitions in the literature. Potential risk factors for PPOI were identified from previous studies, and their predictive ability was evaluated using Bayesian model averaging (BMA). Results are presented as posterior effect probability (PEP). Evidence of association was categorized as: no evidence (PEP < 50%), weak evidence (50–75%), positive evidence (75–95%), strong evidence (95–99%), and very strong evidence (> 99%). Results: There were 323 patients analyzed (mean age 63.5years, 51% males, 74% laparoscopic, 33% rectal resection). The incidence of PPOI was 19% according to the primary definition, but varied between 11 and 59% when using other definitions. On BMA analysis, intraoperative blood loss (PEP 99%; very strong evidence), administration of any intravenous opioids in the first 48h (PEP 94%; strong evidence), postoperative epidural analgesia (PEP 56%; weak evidence), and non-compliance with intra-operative fluid management protocols (3ml/kg/h for laparoscopic and 5ml/kg/h for open; PEP 55%, weak evidence) were predictors of PPOI. Conclusions: The incidence of PPOI after colorectal surgery is high even within an established ERP and varied considerably by diagnostic criteria, highlighting the need for a consensus definition. The use of intravenous opioids is a modifiable strong predictor of PPOI within an ERP, while the role of epidural analgesia and intraoperative fluid management should be further evaluated.
- Published
- 2019
39. Systematic review and meta-analysis of refractometry for diagnosis of inadequate transfer of passive immunity in dairy calves: Quantifying how accuracy varies with threshold using a Bayesian approach
- Author
-
Y. Lu, Sébastien Buczinski, Nandini Dendukuri, Munashe Chigerwe, and Gilles Fecteau
- Subjects
040301 veterinary sciences ,medicine.medical_treatment ,030231 tropical medicine ,Bayesian probability ,Population ,Passive immunity ,0403 veterinary science ,03 medical and health sciences ,0302 clinical medicine ,Food Animals ,Pregnancy ,Statistics ,Animals ,Medicine ,education ,Brix ,education.field_of_study ,business.industry ,Colostrum ,Diagnostic test ,Bayes Theorem ,04 agricultural and veterinary sciences ,Refractometry ,Animals, Newborn ,Meta-analysis ,Cattle ,Female ,Animal Science and Zoology ,False positive rate ,business ,Immunity, Maternally-Acquired - Abstract
Inadequate transfer of passive immunity (TPI) is associated with increased risk for calfhood disease and increased risk of mortality and morbidity. Accurately diagnosing calves and herds with inadequate TPI is of primary importance and brix (BRIX) or classical refractometer (REF) devices are more practical for this purpose than measuring the serum immunoglobulin G concentration in neonatal calves. We previously reported a systematic review and meta-analysis for quantifying the pooled accuracy of BRIX and REF for detecting calves with serum IgG < 10 g/L noting that sparse data were available especially because studies did not report the same thresholds. We updated the previous systematic review using different methods that accounted for the test results distribution in calves with or without inadequate TPI. With this approach, all reported cut-offs for a specific study are used in that Bayesian approach that quantifies how accuracy varied among all reported thresholds. Five new manuscripts were included, which represented 4 new studies since the initial study was performed. A total of 11 REF and 9 BRIX studies were available. The meta-analytic methods allowed reporting variation of the true and false positive rate across and among all reported cut-offs. Pooled points estimates (95 % Bayesian credible intervals) for sensitivity (Se) and specificity (Sp) of REF < 5.5 g/L were 86.1 % (68.5-97.9%) and 76.2 % (65.9-88.4%) whereas BRIX < 8.4 % was associated with Se of 91.6 % (77.2-99.5%) and Sp of 88.2 % (65.4-99.8%). Interestingly, the accuracy (Se + Sp-1) was generally higher for BRIX than for REF at the reported cut-offs. Besides the benefit of providing pooled estimates for all reported and unreported BRIX and REF thresholds, the general framework used in this study could potentially be used in many veterinary diagnostic tests studies that reported multiple thresholds accounting for potentially different tests distributions in population with and without the target condition.
- Published
- 2021
40. Modern obstetrics: beyond early delivery for fetal or maternal compromise
- Author
-
Nandini Dendukuri, Kathleen H. Chaput, Neda Razaz, K.S. Joseph, Yasser Sabr, Natalie V. Scime, Giulia M. Muraca, Sarka Lisonkova, Sid John, and Amélie Boutin
- Subjects
EARLY DELIVERY ,medicine.medical_specialty ,Compromise ,media_common.quotation_subject ,medicine.medical_treatment ,law.invention ,03 medical and health sciences ,Fetus ,0302 clinical medicine ,Randomized controlled trial ,Pregnancy ,law ,medicine ,Humans ,030212 general & internal medicine ,media_common ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Prenatal Care ,General Medicine ,medicine.disease ,3. Good health ,Perinatal morbidity ,Labor induction ,Gestation ,Female ,business - Abstract
The ARRIVE trial showed that adverse perinatal outcomes among low-risk nulliparous women at 39 weeks’ gestation were lower following labor induction (4.3%) compared with expectant management (5.4%; P value 0.049). Although this difference was deemed to be not statistically significant (since the significance threshold had been set at 0.046), there is a need to interpret trial results using a Bayesian approach and to review the conceptual significance of trial findings. The ARRIVE trial hypothesis represents a challenge to the central paradigm of modern obstetrics because it abandons maternal or fetal compromise as a pre-requisite for early delivery. The P value function based on the ARRIVE trial shows that study findings are not consistent with even a modest increase in adverse perinatal outcomes following labor induction for 39 weeks’ gestation, and instead, consistent with a substantial reduction in adverse perinatal outcomes. Physiologic evidence, epidemiologic evidence (on gestational age-specific rates of pregnancy complications, fetal growth-restriction and perinatal morbidity and mortality), and meta-analyses of related randomized trials show that pregnancies accrue small and progressively increasing risks of adverse outcomes at later gestation. Bayesian analysis, based on previous randomized trials updated with ARRIVE trial results, also shows that labor induction for 39 weeks’ gestation has a protective effect with regard to adverse perinatal outcomes. Obstetricians need to be cognizant of this balance of risks and benefits with regard to labor induction and expectant management at 39 weeks’ gestation and beyond, though as always, the ultimate valuation in decision-making has to be guided by principles of patient autonomy.
- Published
- 2021
41. HEALTH PROFESSIONAL LEVEL BARRIERS TO LIVING DONOR KIDNEY TRANSPLANTATION: A MIXED METHODS STUDY
- Author
-
Nandini Dendukuri, Julio F. Fiore, Renata Iskander, Catherine Weber, Marcelo Cantarovich, Marie-Chantal Fortin, Ahsan Alam, and Shaifali Sandal
- Subjects
Transplantation ,medicine.medical_specialty ,Health professionals ,business.industry ,Family medicine ,medicine ,medicine.disease ,business ,Living donor ,Kidney transplantation - Published
- 2020
42. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
- Author
-
Manali Mukherjee, James G. Martin, Kjetil Ask, Stephanie Tran, Parameswaran Nair, Chynna Huang, Tanvi Javkar, Hajar Al-Hayyan, Catherine Lemière, Ronald Olivenstein, Anmar Ayoub, Nandini Dendukuri, Mylène Bertrand, Anna Dvorkin-Gheva, Louis-Philippe Boulet, Marie-Eve Boulay, David Felipe Forero, Melanie Kjarsgaard, Katherine Radford, Jayant Cherukat, Anurag Bhalla, and Spencer Revill
- Subjects
Pulmonary and Respiratory Medicine ,Canada ,03 medical and health sciences ,0302 clinical medicine ,Reslizumab ,Prednisone ,Eosinophilic ,medicine ,Humans ,Anti-Asthmatic Agents ,030212 general & internal medicine ,Interleukin 5 ,Asthma ,business.industry ,Autoantibody ,Antibodies, Monoclonal ,medicine.disease ,Eosinophils ,030228 respiratory system ,Immunology ,Sputum ,Interleukin-5 ,medicine.symptom ,business ,Mepolizumab ,medicine.drug - Abstract
BackgroundIn clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs: mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce exacerbations by ∼50–60%.ObjectiveTo observe response to anti-IL-5 mAbs in a real-life clinical setting, and to evaluate predictors of suboptimal response.MethodsIn four Canadian academic centres, predefined clinical end-points in 250 carefully characterised moderate-to-severe asthmatic patients were collected prospectively to assess response to the two anti-IL-5 mAbs. Suboptimal response was determined based on failure to reduce maintenance corticosteroid (MCS) or asthma symptoms scores (Asthma Control Questionnaire (ACQ)) or exacerbations, in addition to persistence of sputum/blood eosinophils. Worsening in suboptimal responders was assessed based on reduced lung function by 25% or increase in MCS/ACQ. A representative subset of 39 patients was evaluated for inflammatory mediators, autoantibodies and complement activation in sputum (by ELISA) and for immune-complex deposition by immunostaining formalin-fixed paraffin-embedded sputum plugs.ResultsSuboptimal responses were observed in 42.8% (107 out of 250) patients treated with either mepolizumab or reslizumab. Daily prednisone requirement, sinus disease and late-onset asthma diagnoses were the strongest predictors of suboptimal response. Asthma worsened in 13.6% (34 out of 250) of these patients. The majority (79%) of them were prednisone-dependent. Presence of sputum anti-eosinophil peroxidase immunoglobulin (Ig)G was a predictor of suboptimal response to an anti-IL-5 mAb. An increase in sputum C3c (marker of complement activation) and deposition of C1q-bound/IL-5-bound IgG were observed in the sputa of those patients who worsened on therapy, suggesting an underlying autoimmune-mediated pathology.ConclusionA significant number of patients who meet currently approved indications for anti-IL5 mAbs show suboptimal response to them in real-life clinical practice, particularly if they are on high doses of prednisone. Monitoring blood eosinophil count is not helpful to identify these patients. The concern of worsening of symptoms associated with immune-complex mediated complement activation in a small proportion of these patients highlights the relevance of recognising airway autoimmune phenomena and this requires further evaluation.
- Published
- 2020
43. Time-Series Analysis of Health Care–Associated Infections in a New Hospital With All Private Rooms
- Author
-
Charles Frenette, Nandini Dendukuri, Emily G. McDonald, and Todd C. Lee
- Subjects
Hand washing ,medicine.medical_specialty ,MRSA colonization ,business.industry ,010102 general mathematics ,Clostridium difficile ,medicine.disease_cause ,Rate ratio ,01 natural sciences ,Methicillin-resistant Staphylococcus aureus ,03 medical and health sciences ,0302 clinical medicine ,Emergency medicine ,Internal Medicine ,medicine ,Infection control ,Colonization ,Vancomycin-resistant Enterococcus ,030212 general & internal medicine ,0101 mathematics ,business - Abstract
Importance Health care–associated infections are often caused by multidrug-resistant organisms and substantially factor into hospital costs and avoidable iatrogenic harm. Although it is recommended that new facilities be built with single-room, low-acuity beds, this process is costly and evidence of reductions in health care–associated infections is weak. Objective To examine whether single-patient rooms are associated with decreased rates of common multidrug-resistant organism transmissions and health care–associated infections. Design, Setting, and Participants A time-series analysis comparing institution-level rates of new multidrug-resistant organism colonization and health care–associated infections before (January 1, 2013-March 31, 2015) and after (April 1, 2015-March 31, 2018) the move to the hospital with 100% single-patient rooms. In the largest hospital move in Canadian history, inpatients in an older, tertiary care, 417-bed hospital in Montreal, Canada, that consisted of mainly mixed 3- and 4-person ward-type rooms were moved to a new 350-bed facility with all private rooms. Exposures A synchronized move of all patients on April 26, 2015, to a new hospital with 100% single-patient rooms equipped with individual toilets and showers and easy access to sinks for hand washing. Main Outcomes and Measures Rates of nosocomial vancomycin-resistantEnterococcus(VRE) and methicillin-resistantStaphylococcus aureus(MRSA) colonization, VRE and MRSA infection, andClostridioides difficile(formerly known asClostridium difficile) infection (CDI) per 10 000 patient-days. Results Compared with the 27 months before, during the 36 months after the hospital move, an immediate and sustained reduction in nosocomial VRE colonization (from 766 to 209 colonizations; incidence rate ratio [IRR], 0.25; 95% CI, 0.19-0.34) and MRSA colonization (from 129 to 112 colonizations; IRR, 0.57; 95% CI, 0.33-0.96) was noted, as well as VRE infection (from 55 to 14 infections; IRR, 0.30, 95% CI, 0.12-0.75). Rates of CDI (from 236 to 223 infections; IRR, 0.95; 95% CI, 0.51-1.76) and MRSA infection (from 27 to 37 infections; IRR, 0.89, 95% CI, 0.34-2.29) did not decrease. Conclusion and Relevance The move to a new hospital with exclusively single-patient rooms appeared to be associated with a sustained decrease in the rates of new MRSA and VRE colonization and VRE infection; however, the move was not associated with a reduction in CDI or MRSA infection. These findings may have important implications for the role of hospital construction in facilitating infection control.
- Published
- 2019
44. Accuracy of Administrative Health Data for Surveillance of Traumatic Brain Injury: A Bayesian Latent Class Analysis
- Author
-
Oliver Lasry, Judith Marcoux, Nandini Dendukuri, and David L. Buckeridge
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Traumatic brain injury ,Bayesian probability ,Health data ,03 medical and health sciences ,Bayes' theorem ,Young Adult ,0302 clinical medicine ,Sex Factors ,Brain Injuries, Traumatic ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,Child ,Aged ,business.industry ,Incidence (epidemiology) ,Incidence ,Age Factors ,Infant, Newborn ,Quebec ,Infant ,Reproducibility of Results ,Bayes Theorem ,Emergency department ,Middle Aged ,medicine.disease ,Latent class model ,Data Accuracy ,Latent Class Analysis ,Child, Preschool ,Population Surveillance ,Emergency medicine ,Female ,business ,030217 neurology & neurosurgery - Abstract
BACKGROUND Traumatic brain injury surveillance provides information for allocating resources to prevention efforts. Administrative data are widely available and inexpensive but may underestimate traumatic brain injury burden by misclassifying cases. Moreover, previous studies evaluating the accuracy of administrative data surveillance case definitions were at risk of bias by using imperfect diagnostic definitions as reference standards. We assessed the accuracy (sensitivity/specificity) of traumatic brain injury surveillance case definitions in administrative data, without using a reference standard, to estimate incidence accurately. METHODS We used administrative data from a 25% random sample of Montreal residents from 2000 to 2014. We used hierarchical Bayesian latent class models to estimate the accuracy of widely used traumatic brain injury case definitions based on the International Classification of Diseases, or on head radiologic examinations, covering the full injury spectrum in children, adults, and the elderly. We estimated measurement error-adjusted age- and severity-specific incidence. RESULTS The adjusted traumatic brain injury incidence was 76 (95% CrI = 68, 85) per 10,000 person-years (underestimated as 54 [95% CrI = 54, 55] per 10,000 without adjustment). The most sensitive case definitions were radiologic examination claims in adults/elderly (0.48; 95% CrI = 0.43, 0.55 and 0.66; 95% CrI = 0.54, 0.79) and emergency department claims in children (0.45; 95% CrI = 0.39, 0.52). The most specific case definitions were inpatient claims and discharge abstracts (0.99; 95% CrI = 0.99, 1.00). We noted strong secular trends in case definition accuracy. CONCLUSIONS Administrative data remain a useful tool for conducting traumatic brain injury surveillance and epidemiologic research when measurement error is adjusted for.
- Published
- 2018
45. Estimating diagnostic accuracy of fecal culture in liquid media for the detection of Mycobacterium avium subsp. paratuberculosis infections in Québec dairy cows: A latent class model
- Author
-
Julie Paré, Vincent Wellemans, Nandini Dendukuri, Gilles Fecteau, Juan Carlos Arango-Sabogal, Geneviève Côté, Olivia Labrecque, Ian Schiller, Sébastien Buczinski, and Jean-Philippe Roy
- Subjects
0301 basic medicine ,040301 veterinary sciences ,Bayesian probability ,Paratuberculosis ,Cattle Diseases ,Enzyme-Linked Immunosorbent Assay ,Biology ,Sensitivity and Specificity ,0403 veterinary science ,03 medical and health sciences ,Feces ,Food Animals ,Statistics ,Covariate ,Prior probability ,medicine ,Animals ,Bacteriological Techniques ,Conditional dependence ,Quebec ,Reproducibility of Results ,04 agricultural and veterinary sciences ,medicine.disease ,Latent class model ,Fecal culture ,Mycobacterium avium subsp. paratuberculosis ,030104 developmental biology ,Herd ,Animal Science and Zoology ,Cattle ,Female - Abstract
A latent class model fit within a Bayesian framework was used to estimate the sensitivity and specificity of individual fecal culture (IFC) in liquid medium (Para TB culture liquid medium and BACTEC MGIT 960 system) for the detection of Mycobacterium avium subsp. paratuberculosis (MAP) infections in Quebec dairy cows. As a secondary objective, the within-herd paratuberculosis prevalence was estimated. A dataset including 21 commercial Quebec dairy herds participating in previous research projects was retrospectively analyzed. In total, 1386 adult cows on which both IFC and serum-ELISA were available were included. The selected latent class model assumed conditional dependence between the tests. Non-informative priors for IFC accuracy and paratuberculosis prevalence were used while informative priors, obtained from the literature, were used for serum-ELISA accuracy. The WinBUGS statistical freeware was used to obtain posterior estimates (medians and 95% Bayesian credibility intervals (95% BCI)) for each parameter. The sensitivity and specificity estimates for IFC were 34.4% (95% BCI: 20.3-66.1) and 99.5% (95% BCI: 98.6-100), respectively. Sensitivity and specificity for serum-ELISA were 27.3% (95% BCI: 18.1-38.3) and 97.4% (95% BCI: 96.6-98.0). Median paratuberculosis within herd prevalence was estimated to be 0.3% (0-3.3). In conclusion, a higher sensitivity of IFC compared to serum-ELISA was observed both in the unconditional and conditional dependent models. Since the sensitivity of both IFC and serum-ELISA was relatively low, conditional dependence between the tests is more likely in the true disease positive animals. We hypothesize that conditional dependence arises because an unmeasured covariate influences the performance of both tests among disease positive animals causing both tests to incorrectly misclassify the animal as negative. One limitation of this study was the very low within herd prevalence of the participant herds.
- Published
- 2018
46. Clostridium difficile: Investigating transmission patterns between infected and colonized patients using whole genome sequencing
- Author
-
Mark H. Wilcox, Ian Schiller, Yves Longtin, Frédéric Raymond, Ling Yuan Kong, Jacques Corbeil, Anne-Marie Bourgault, A S Walker, Vivian G. Loo, Sophie Michaud, Baldwin Toye, Nandini Dendukuri, Louise Poirier, Nathalie Turgeon, Paul Brassard, Rodica Gilca, Matthew Oughton, Derrick W. Crook, Eric Frost, Andre Dascal, and David W Eyre
- Subjects
Diarrhea ,0301 basic medicine ,Microbiology (medical) ,DNA, Bacterial ,genetic structures ,030106 microbiology ,Virulence ,Single-nucleotide polymorphism ,Article ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Humans ,Colonization ,030212 general & internal medicine ,Typing ,Articles and Commentaries ,Whole genome sequencing ,Cross Infection ,Whole Genome Sequencing ,Transmission (medicine) ,business.industry ,Clostridioides difficile ,Clostridium difficile ,3. Good health ,Infectious Diseases ,Carrier State ,Clostridium Infections ,Multilocus sequence typing ,business ,Genome, Bacterial - Abstract
Background Whole genome sequencing (WGS) studies can enhance our understanding of the role of patients with asymptomatic Clostridium difficile colonization in transmission. Methods Isolates obtained from patients with Clostridium difficile infection (CDI) and colonization identified in a study conducted during 2006 - 2007 at six Canadian hospitals underwent typing by pulsed-field gel electrophoresis, multilocus sequence typing, and WGS. Isolates from incident CDI cases not in the initial study were also sequenced where possible. Ward movement and typing data were combined to identify plausible donors for each CDI case, as defined by shared time and space within predefined limits. Proportions of plausible donors for CDI cases that were colonized, infected, or both were examined. Results Five hundred and fifty-four isolates were sequenced successfully, 353 from colonized and 201 from CDI cases. The NAP1/027/ST1 strain was the most common strain, found in 124 (62%) of infected and 92 (26%) of colonized patients. A donor with a plausible ward link was found for 81 CDI cases (40%) using WGS with a threshold of ≤2 single nucleotide variants to determine relatedness. Sixty-five (32%) CDI cases could be linked to both infected and colonized donors. Exclusive linkages to infected and colonized donors were found for 28 (14%) and 12 (6%) CDI cases, respectively. Conclusion Colonized patients contribute to transmission, but CDI cases are more likely linked to other infected patients than colonized patients in this cohort with high rates of NAP1/027/ST1 strain, highlighting the importance of local prevalence of virulent strains in determining transmission dynamics.
- Published
- 2018
47. Health Care-Associated Infections after Subarachnoid Hemorrhage
- Author
-
Najayeb Alabdulraheem, Yasser B. Abulhasan, Charles Frenette, Nandini Dendukuri, Mark R. Angle, Susan P. Rachel, and Ian Schiller
- Subjects
Male ,medicine.medical_specialty ,animal structures ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Risk Factors ,Epidemiology ,medicine ,Infection control ,Humans ,030212 general & internal medicine ,Aged ,Cross Infection ,Infection Control ,business.industry ,Incidence (epidemiology) ,Incidence ,Ventilator-associated pneumonia ,virus diseases ,Vasospasm ,Bayes Theorem ,Length of Stay ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Intensive care unit ,Pneumonia ,Intensive Care Units ,Intraventricular hemorrhage ,Catheter-Related Infections ,Emergency medicine ,Urinary Tract Infections ,Surgery ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Objective Health care–associated infections (HAIs) after subarachnoid hemorrhage (SAH) are prevalent; however, data describing epidemiology of infection are limited. This study reports incidence rates, risk factors, and the resulting SAH patient-related outcomes. Methods We studied the incidence of HAIs acquired in the intensive care unit (ICU) over a 6-year period. We used Bayesian Model Averaging to identify risk factors associated with an increased risk of HAIs, particularly urinary tract infections (UTI), pneumonia, and ventriculostomy-associated infections (VAI). We also examined the impact of HAIs on risk of vasospasm, ICU and hospital length of stay, and discharge disposition and adjusted for other risk factors. Results Of 419 patients with SAH, 66 (15.8%) developed 79 HAI episodes. Mean HAI incidence rates (per 1000 ICU-days) were UTI, 7.1; pneumonia, 4.3; and VAI, 2.4. The admission characteristic associated with increased risk of overall HAI, UTI, and VAI was diabetes mellitus. Hunt and Hess grades III–V were associated with increased risk of overall HAI and VAI. Male gender, intraventricular hemorrhage, and blood glucose level (>10) were associated with increased risk of pneumonia, whereas the incidence was lower in the presence of steroids. HAI was associated with increased length of stay of 10 ICU-days and 22 hospital-days, but not vasospasm or poor discharge disposition. Conclusions HAIs are serious complications after SAH associated with prolonged ICU and hospital length of stay. Additional rigorous infection control measures aimed at patients with identifiable risk factors should trigger prevention, and early detection of nosocomial infections is warranted to further reduce the prevalence of HAIs.
- Published
- 2018
48. Cardiac Resynchronization Therapy in Heart Failure: Do Evidence-Based Guidelines Follow the Evidence?
- Author
-
Nandini Dendukuri, James M. Brophy, Eva Suarthana, and Nisha D. Almeida
- Subjects
Male ,medicine.medical_specialty ,Evidence-based practice ,medicine.medical_treatment ,Cardiac resynchronization therapy ,030204 cardiovascular system & hematology ,law.invention ,Cardiac Resynchronization Therapy ,03 medical and health sciences ,QRS complex ,0302 clinical medicine ,Meta-Analysis as Topic ,Randomized controlled trial ,law ,medicine ,Humans ,Ventricular Function ,cardiovascular diseases ,Healthcare Disparities ,Ventricular dyssynchrony ,Intensive care medicine ,Randomized Controlled Trials as Topic ,Heart Failure ,Evidence-Based Medicine ,Ejection fraction ,business.industry ,030503 health policy & services ,Recovery of Function ,Canadian Cardiovascular Society ,medicine.disease ,Treatment Outcome ,Heart failure ,Practice Guidelines as Topic ,cardiovascular system ,Female ,0305 other medical science ,Cardiology and Cardiovascular Medicine ,business ,Systematic Reviews as Topic - Abstract
Cardiac resynchronization therapy (CRT) for ventricular dyssynchrony in patients with heart failure has seen a steady increase worldwide; yet evidence of its effectiveness in certain subgroups is unclear. Given the high cost and risk of complications associated with these implants and their replacements, there is a need for clear clinical practice guidelines. In this report, we explore the variability of recommendations in published clinical practice guidelines and determine the extent of their evidential support. We conducted an electronic search for the most recent clinical practice guidelines and health technology assessments (HTAs) pertaining to a first implant of CRT in patients with heart failure and a systematic review of all published randomized controlled trials (RCTs) that evaluated the efficacy of CRT in heart failure patients with left ventricular dyssynchrony.1 We evaluated the concordance between recommendations on CRT use and evidence from the corresponding RCTs and meta-analyses of these RCTs. Because most recommendations were made within patient subgroups (such as New York Heart Association [NYHA] class, QRS morphology, and QRS interval), we determined how well represented these subgroups were in the major trials. We identified 4 clinical practice guidelines and 4 HTAs (Table I in the Data Supplement). Figure compares the guidelines for first-time use of CRT issued by the 4 professional societies and 2 of the HTAs. Two other HTAs were not included in Figure because they did not make recommendations by subgroups. Figure. Comparison of guidelines issued by the professional societies and health technology assessments (HTAs) for the use of cardiac resynchronization therapy (CRT) in heart failure. *For patients who have left ventricular ejection fraction ≤30%, †for patients who have left ventricular ejection fraction ≤35%, and ‡strong statistical and clinical evidence of benefit. ACCF/AHA indicates American College of Cardiology Foundation/American Heart Association; CCS, Canadian Cardiovascular Society; CRT-D, cardiac resynchronization therapy …
- Published
- 2017
49. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis
- Author
-
Andrew R. DiNardo, Nandini Dendukuri, Karen R Steingart, Anna M. Mandalakas, Ian Schiller, Anne Detjen, Dick Menzies, and Jacinta Leyden
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Tuberculosis ,Adolescent ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,Induced sputum ,medicine.disease_cause ,Sensitivity and Specificity ,Article ,Smear microscopy ,Pulmonary tuberculosis ,Internal medicine ,Tuberculosis diagnostics ,medicine ,Humans ,Child ,Tuberculosis, Pulmonary ,business.industry ,Infant ,Reproducibility of Results ,medicine.disease ,Gastric lavage ,Molecular Diagnostic Techniques ,Child, Preschool ,Meta-analysis ,Immunology ,business - Abstract
Summary Background Microbiological confirmation of childhood tuberculosis is rare because of the difficulty of collection of specimens, low sensitivity of smear microscopy, and poor access to culture. We aimed to establish summary estimates for sensitivity and specificity of of the Xpert MTB/RIF assay compared with microscopy in the diagnosis of pulmonary tuberculosis in children. Methods We searched for studies published up to Jan 6, 2015, that used Xpert in any setting in children with and without HIV infection. We systematically reviewed studies that compared the diagnostic accuracy of Xpert MTB/RIF (Xpert) with microscopy for detection of pulmonary tuberculosis and rifampicin resistance in children younger than 16 years against two reference standards—culture results and culture-negative children who were started on anti-tuberculosis therapy. We did meta-analyses using a bivariate random-effects model. Findings We identified 15 studies including 4768 respiratory specimens in 3640 children investigated for pulmonary tuberculosis. Culture tests were positive for tuberculosis in 12% (420 of 3640) of all children assessed and Xpert was positive in 11% (406 of 3640). Compared with culture, the pooled sensitivities and specificities of Xpert for tuberculosis detection were 62% (95% credible interval 51–73) and 98% (97–99), respectively, with use of expectorated or induced sputum samples and 66% (51–81) and 98% (96–99), respectively, with use of samples from gastric lavage. Xpert sensitivity was 36–44% higher than was sensitivity for microscopy. Xpert sensitivity in culture-negative children started on antituberculosis therapy was 2% (1–3) for expectorated or induced sputum. Xpert's pooled sensitivity and specificity to detect rifampicin resistance was 86% (95% credible interval 53–98) and 98% (94–100), respectively. Interpretation Compared with microscopy, Xpert offers better sensitivity for the diagnosis of pulmonary tuberculosis in children and its scale-up will improve access to tuberculosis diagnostics for children. Although Xpert helps to provide rapid confirmation of disease, its sensitivity remains suboptimum compared with culture tests. A negative Xpert result does not rule out tuberculosis. Good clinical acumen is still needed to decide when to start antituberculosis therapy and continued research for better diagnostics is crucial. Funding WHO, Global TB Program of Texas Children's Hospital.
- Published
- 2015
50. Bayesian estimation of the accuracy of the calf respiratory scoring chart and ultrasonography for the diagnosis of bovine respiratory disease in pre-weaned dairy calves
- Author
-
Sébastien Buczinski, Nandini Dendukuri, and Terri L Ollivett
- Subjects
Veterinary medicine ,medicine.medical_specialty ,Cross-sectional study ,Respiratory Tract Diseases ,New York ,Bovine Respiratory Disease Complex ,Bovine respiratory disease ,Sensitivity and Specificity ,Food Animals ,Chart ,Internal medicine ,Prevalence ,medicine ,Credible interval ,Animals ,Cutoff ,Respiratory system ,Ultrasonography ,Bayes estimator ,Conditional dependence ,business.industry ,Quebec ,Bayes Theorem ,medicine.disease ,Animals, Suckling ,Respiratory Function Tests ,Cross-Sectional Studies ,Cattle ,Female ,Animal Science and Zoology ,business - Abstract
There is currently no gold standard method for the diagnosis of bovine respiratory disease (BRD) complex in Holstein pre-weaned dairy calves. Systematic thoracic ultrasonography (TUS) has been used as a proxy for BRD, but cannot be directly used by producers. The Wisconsin calf respiratory scoring chart (CRSC) is a simpler alternative, but with unknown accuracy. Our objective was to estimate the accuracy of CRSC, while adjusting for the lack of a gold standard. Two cross sectional study populations with a high BRD prevalence (n=106 pre-weaned Holstein calves) and an average BRD prevalence (n=85 pre-weaned Holstein calves) from North America were studied. All calves were simultaneously assessed using CRSC (cutoff used ≥ 5) and TUS (cutoff used ≥ 1cm of lung consolidation). Bayesian latent class models allowing for conditional dependence were used with informative priors for BRD prevalence and TUS accuracy (sensitivity (Se) and specificity (Sp)) and non-informative priors for CRSC accuracies. Robustness of the model was tested by relaxing priors for prevalence or TUS accuracy. The SeCRSC (95% credible interval (CI)) and SpCRSC were 62.4% (47.9-75.8) and 74.1% (64.9-82.8) respectively. The SeTUS was 79.4% (66.4-90.9) and SpTUS was 93.9% (88.0-97.6). The imperfect accuracy of CRSC and TUS should be taken into account when using those tools to assess BRD status.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.